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The Cannabinoid Receptor 2 (CB2), a member of the endocannabinoid system belongs to the 
Rhodopsin family of G-Protein Coupled Receptors (GPCRs). It is expressed mainly in the 
immune cells and exerts immunomodulatory roles in normal and pathophysiological conditions. 
Therapeutic modulation of the CB2 presents a promising strategy for the treatment of several 
diseases like multiple myeloma, osteoporosis, pain etc. In the face of the huge therapeutic 
importance of the CB2, high resolution structural information and mechanistic details of receptor 
activation are poorly understood. This principally owes to the paucity of large amounts of 
purified recombinant functionally active CB2 in-vitro. GPCRs and most eukaryotic membrane 
proteins pose a formidable challenge for recombinant expression and purification. Limitations 
include low expression, toxicity towards host cells, loss of function etc. In an effort to produce 
functionally active recombinant CB2 that can be used for subsequent structural studies, in the 
present study, we have developed two distinct approaches for the functional expression and 
purification of CB2 from the E. coli. 
In the first approach we used Mistic, an integral membrane protein expression enhancer, 
and TarCF, a C-terminal fragment of the bacterial chemosensory transducer Tar, as fusion 
partners at the N'- and C'-terminal respectively of the CB2 for its membrane targeted expression 
in the E. coli C43(DE3). Using the fusion partners individually or in combination, we found that 
CB2 fusion protein expression was maximal when both partners were used in combination. More 
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importantly, the fusion protein Mistic–CB2–TarCF localized to the E. coli membrane and these 
extracted membrane fractions exhibited functional binding activities with known CB2 ligands 
including CP55,940, WIN55,212-2 and SR144,528.  
In the second approach, we expressed the CB2, in fusion with GST at its N'- terminal, as 
inactive inclusion bodies (IBs). The receptor protein was engineered to carry a 6 Histidine (His6) 
tag at its C'-terminal for subsequent immobilized metal affinity chromatographic (IMAC) 
purification. Pilot studies supported extraction of GST-CB2 in a denaturing detergent, N- 
Lauroyl sarcosinate (Sarkosyl) followed by exchange to Dodecyl-beta-D-Maltoside (DDM) for 
“on-column” cleavage. Post size exclusion chromatography, eluted purified monodisperse CB2 
were subjected to refolding either in lipidic (DMPC) or proteic (Amphipol) environments. CB2 
refolded in DMPC exhibited functional binding activities with known CB2 ligands including CP 
55,940, SR144528 and PY2-64. 
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1.0  INTRODUCTION 
1.1 RECENT ADVANCES IN EXPRESSION AND PURIFICATION OF GPCRS 
1.1.1 The GPCR Superfamily 
G-protein coupled receptors (GPCRs) comprise one of the largest superfamily of human receptor 
proteins which act as signal transducers. These receptors initiate internal signaling events in 
response to huge array of external stimuli known as “signals”. About 4% of the protein coding 
genome code for these receptors in humans (Bjarnadottir et al., 2006). Overall, GPCRs are 
classified into 6 groups based on their structural and functional similarities (Attwood and 
Findlay, 1994; Foord et al., 2005; Kolakowski, 1994).  These are: Class A – Rhodopsin-like, 
Class B – Secretin receptor family, Class C- Metabotropic glutamate, Class D- Fungal mating 
pheromone, Class E- Cyclic AMP receptors and Class F- Frizzled/Smoothened (Figure 1.1). 
Amongst these, the Rhodopsin-like (class A) family of GPCRs comprises nearly 85% of the 
entire family of GPCRs and is further subdivided into 19 subgroups A1 through A19 (Dorsam 
and Gutkind, 2007). GPCRs respond to a variety of signals which include hormones, growth 
factors and endogenous ligands (Gaidamovich et al., 1978). Due to the huge diversity of 
activating ligands, GPCRs play a diverse array of roles in various physiological processes that 
include regulation of vision, smell, mood, behavior, immune modulation and the maintenance of 
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several other homeostatic processes (Kang and Koo, 2012; Sumiyoshi et al., 2013; Wasik et al., 
2011; Zhou et al., 2012). Despite their functional diversity, all GPCRs share a common structural 
motif which is characterized by an extracellular amino (N') terminal domain, seven 
transmembrane domains (TM 1-7) and an intracellular carboxy (C')-terminal domain. The 
transmembrane domains are connected by three extracellular (EL 1-3) and three intracellular (IL 
1-3) loops. The tertiary structures of these receptors are arranged as a barrel with a central core 
region which generally houses the ligand binding site. In cases where the ligand is a protein or a 
large peptide hormone, the extracellular loops 1 and 2 serve as ligand binding sites. The N'- and 
the C'-terminals play independent roles in ligand recognition and post-translational modification 
respectively (Kawamura et al., 1989; Kristiansen, 2004). Upon ligand binding and activation, the 
receptors undergo conformational change in the transmembrane region. These rearrangements 
are facilitated by the disruption of the ionic linkage and the toggle of the conserved tryptophan 
residue within the transmembrane domains of Rhodopsin family of GPCRs (Kobilka and Deupi, 
2007). The movements within the transmembrane region allow the exposure of the cognate G 
protein binding site which leads to binding of the G protein and subsequent signal transduction 
(Trzaskowski et al., 2012).Recent studies suggest that GPCRs have their own intrinsic degree of 
activity independent of ligand binding, known as basal constitutive activity (Kobilka and Deupi, 
2007). However the presence of activating ligands results in formation of “activated GPCR” 
which is capable of G protein binding. G proteins are made up of Gα and Gβγ domains. The Gα 
subunit houses the GTP exchange factor (GEF) region of the G protein. Post ligand binding the 
GEF in an activated G protein recruits a GTP leading to the dissociation of the Gα and the Gβγ 
subunits, which independently have limited downstream activation properties. The subsequent 
role of the individual Gα subunit depends on the cognate GPCR which also determines the 
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downstream signaling pathway. The stimulatory Gα unit (Gαs) activates the cellular protein 
adenylate cyclase and lead to increase in cyclic AMP (cAMP) levels while the Gαi (inhibitory) 
leads to the inhibition of the adenylase cyclase activity resulting in reduction of cAMP levels in 
the cell (Simonds, 1999). The activated Gβγ moiety has independent signal transduction 
capabilities and acts particularly on different ion channels e.g. G protein regulated inward 
rectifying ion channels (GIRKs) and N-type voltage gated Ca2+ channels (Wickman and 
Clapham, 1995). Downstream signaling events following GPCR activation are complicated and 
are extremely diverse due to the presence of a large array of secondary effectors which are 
specific to the GPCR.  
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Figure 1.1. The organization of GPCR superfamily and known structures  
(A) The GPCR superfamily is organized into five subfamilies based on their sequential 
similarities. The majority of the receptor  proteins belong to the Rhodopsin family 
GPCRs . (B)  Family tree of the entire GPCR superfamily showing the number and 
position of the GPCRs with known structure. 
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1.1.2 Necessity and challenges in the expression and purification of GPCRs 
GPCRs altogether make up one of the largest class of drug targets. Due to their significant roles 
in   various physiological processes they are widely implicated in a large number of 
pathophysiological conditions as mentioned in the previous section. It has now also been 
established that they are involved in the growth and metastasis of several different types of 
tumors.  Substantial amount of research both in the industry and the academia is focused towards 
understanding the mechanism of action of these receptors.  Alongside, a closely related focus of 
most researchers is the design and development of more selective and potent ligands for 
modulating the action of these receptors for the desired therapeutic effect(s). Despite the huge 
therapeutic implications of the receptors, the high resolution structure of the receptor is available 
for only twenty two out of eight hundred GPCRs  (Venkatakrishnan et al., 2013) (Figure 1.1). 
This lag in the number of high resolution structure or mechanistic details of activation process 
creates a formidable challenge in GPCR drug discovery, particularly in structure based drug 
design. Several other computational or ligand based drug discovery methods have been 
developed to work around this barrier. These methods rely on screening large ligand libraries in-
silico. However, generated lead molecules may suffer from the lack of potency and specificity. 
Lack of specificity is a huge problem when different subtypes of the same receptor are present 
and have diverse physiological roles, for example the Cannabinoid Receptors 1 and 2 (CB1 and 
CB2) which will be discussed in much greater detail in Section 1.3.  
The challenges in obtaining high resolution X-ray crystal or Nuclear Magnetic Resonance 
(NMR) structure of a GPCR are manifold. Due to the transmembrane structure of the GPCRs and 
the inefficient membrane insertion process the over-expression of the GPCR in prokaryotic 
expression hosts prove toxic. The yield of recombinant GPCR is comparatively much lower than 
 6 
the yield of globular or soluble proteins in an expression host. Extraction, enrichment and 
purification of the GPCRs require the presence of detergents which may negatively affect the 
GPCR yield and stability. These detergents in residual amounts may also deter the formation and 
growth of crystals. However certain amphipathic detergents may be well tolerated during crystal 
growth in combination with lipid or lipid-like molecules. Finally, GPCRs have very less area for 
the formation of crystal contacts. The presence of the intracellular loop3 and other regions of 
inherent flexibility are likely impede or may totally prevent the growth and formation of crystals. 
Due to the presence of several roadblocks towards high resolution structure of GPCRs, 
optimization of several parameters at each step of the process is required (Figure 1.2). 
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Recombinant receptor 
(Active/ Inactive)
Extracted receptor  stabilized in 
detergent micelles
Receptor stabilized in membrane 
mimetic environment
 
Figure 1.2. Challenges towards generation of stabilized GPCR in-vitro. 
Recombinant receptor production  is toxic for the host organism. The 
produced receptor requires detergent for extraction and solubilization in the 
buffer which can then be subjected to chromatographic purification. Finally 
the detergent solubilized receptor requires to be exchanged to the stabilizing 
environment to obtain the receptor in the correct / native structural 
disposition. 
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1.1.3 Current methods and developments for GPCR expression and purification 
The challenging nature of membrane protein GPCR expression has led to the trial and 
development of optimized processes for the expression of GPCRs. Several hosts such as bacteria 
H. salinarium, L. lactis ,several other species of yeasts like S. cerevesiae and S. pombe and insect 
cells like Sf9 and Hi5 have also been used for GPCR expression.  
Expression of the receptor protein in the E.coli results in the formation of insoluble 
aggregates known as inclusion bodies (IBs) (Bane et al., 2007).  Previous studies in our lab were 
directed towards structural studies of individual CB2 transmembrane helices   (Xie et al., 2004; 
Zhang and Xie, 2008; Zheng et al., 2005). Expression of eukaryotic membrane protein has been 
achieved in the E. coli by designing and expressing fusion proteins which carry bacterial 
membrane proteins in either or both terminals of the protein of interest. This method was 
pioneered by Grisshamer et. al has been applied for many GPCRs  (Grisshammer, 2009; 
Grisshammer et al., 1993; Grisshammer et al., 1994; Grisshammer and Tate, 1995) including the 
studies of Yeliseev et. al on the CB2 receptor (Berger et al., 2010; Krepkiy et al., 2007; Krepkiy 
et al., 2006; Yeliseev et al., 2005). Many further modifications of this method were made and 
newer fusion partners discovered and validated including our previously reported study 
(Chowdhury et al., 2012).  Functional GPCR production and purification was achieved with 
varying degree of success from these constructs however it is challenging to maintain the 
structural disposition of the receptor while extraction, chromatographic steps, tag removal etc.  
Baculovirus infected Spodoptera  frugiperda (Sf9)  cells have successfully led to the 
production of GPCRs yielding crystal structures (Aloia et al., 2009).  Sf9 cells have the 
advantage of a eukaryotic   transcription and translation machinery and a eukaryotic membrane 
composition which favors eukaryotic GPCR expression, membrane translocation and functional 
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activity (Aloia et al., 2009). However, crystal formation in GPCRs requires stabilization of the inherently 
flexible intracellular loop 3 (IL3) region by the more stable and crystallizable T4Lysozyme or 
stabilized by the presence of Anti-IL3 antibody Fab fragments (Rasmussen et al., 2011; 
Rasmussen et al., 2007; Rosenbaum et al., 2007; Rosenbaum et al., 2009; Rosenbaum et al., 
2011). The procedure to generate the GPCR chimera involves the critical adjustment to obtain 
the most stabilized receptor while still retaining its complete functional activity both in terms of 
ligand binding and signal transduction.  Nevertheless crystal structure of several key members, 
particularly of the Rhodopsin family GPCRs, e.g. β2-Adrenergic Receptor, A2a Adenosine 
Receptor, Dopamine Receptor, Chemokine Receptor and more recently the Kappa –opoid 
Receptor etc were arrived at by this method (http://gpcr.scripps.edu/).  
Procedure for membrane targeted GPCR expression in E. coli or Sf9 requires the 
generation of functional chimeric GPCR. An entirely different approach is to express the GPCR 
in high amounts as inactive inclusion bodies (IBs) followed by purification and refolding to 
functionally active receptor (Baneres et al., 2011). One of the advantages of producing GPCRs, 
or for that matter, any heterologous gene product as IBs is that they mostly contain the 
recombinant protein in high purity (99%). However the IBs may also contain chaperones and 
membrane fragments. Secondly, the IBs are formed as tight clusters, this self association would 
allow masking the proteolytic sites hence the IBs are much more refractory to proteolytic 
cleavage. The IBs are usually also very stable mechanically and can be isolated and enriched 
from the cell preparations by centrifugation. For several examples e.g. mouse Cannabinoid 
Receptor 1(muCB1), human Parathyroid Hormone Receptor 1(huPTHR1)(Michalke et al., 
2010), Chemokine receptor (Park et al., 2006)and more the yield of membrane protein receptors 
would increase more than thousand folds when expressed as inclusion bodies. 
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Table 1.1. Table illustrating the different expression systems for GPCRs and their associated 
characteristics.  
Modified from (Lundstrom, 2005) 
 
 
 
Expression System 
(host) Advantage Disadvantage Reference 
E. coli 
Membrane 
targeted 
Receptor is 
pharmacologically 
active 
No post-translational 
modification. Fusion 
partners required 
(Luca et al., 
2003) 
Inclusion body 
Much higher 
yields of the 
protein of interest 
Receptor is not 
active, refolding 
required 
(Baneres and 
Parello, 2003) 
Pichia pastoris 
Relatively easy. 
High cell biomass 
obtained 
Clone selection 
difficult, cells very 
sturdy due to the 
presence of thick cell 
wall 
(Weiss et al., 
1998) 
Baculovirus 
Very similar to 
mammalian 
expression system 
Viral stock 
production is slow and 
unstable. 
(Mazina et al., 
1994) 
Mammalian 
Transient Native 
Transfection 
efficiency dependent 
(McAllister et 
al., 1992) 
Stable 
Native and 
inducible. Long 
lasting production 
system 
Long generation 
times, cell lines may 
not be stable 
(Reeves et al., 
2002) 
Cell free translation Simple and fast 
Very low yield of 
recombinant protein, 
insertion to lipid 
bilayer is problematic 
Mikako 
Shirozu, 
unpublished 
data 
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1.2 E.COLI AS A HOST FOR GPCR EXPRESSION AND RELATED 
METHODOLOGIES 
1.2.1 Protein production in the E.coli 
Escherichia coli are a gram negative, facultative anaerobic bacterium. This bacterium is 
commonly found in the lower part of the gastro-intestinal tract of warm blooded mammals. Most 
E. coli are harmless, while some may be the causative agent of food poisoning in humans. These 
rod shaped bacterium is ~ 2 µm long and has a diameter of ~ 0.5 µm (Kubitschek, 1990). The 
mean cell volume of the bacterium is ~0.6-0.7 cubic µm. The E. coli has traditionally been used 
as the workhorse for expression of wide variety of proteins by recombinant DNA technology. An 
explicit understanding of the process of transcription and translation in E. coli allows researchers 
to modulate several steps in the procedure of protein production (Lee, 1996; Russo, 2003). 
Commonly, the E. coli expression system uses the T7 RNA Polymerase system. One of the main 
disadvantages of this system is the high basal level of endogenous protein expression which 
consequently reduces the amount of the exogenous protein produced and the final yield of the 
protein of interest. The development of the T7/lac operon system allows suppression of the basal 
level expression of the protein of interest until the cells have grown to a particular stage in their 
growth curve. At this point, the cells can be induced with the chemical compound Isopropyl β-D-
1-thiogalactopyranoside (IPTG) which is a chemical non-hydrolysable analogue of lactose and 
serves to induce expression of the exogenous protein of interest from its inducible promoter. E. 
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coli pLysS and pLysE strains carry the plasmid for the T7 lysozyme which is the inhibitor of the 
T7 polymerase. The addition of 0.5-1% glucose in the culture media acts as a catabolite repressor 
for a protein under the control of the lac operon (Moses and Prevost, 1966). The optimum growth 
temperature for the E. coli is 37°C. However a culture may be subjected to lower growth 
temperatures as low as ~20°C for the controlled production of recombinant proteins. The E. coli 
is one of the most versatile hosts and perhaps, plays one of the most important role in 
recombinant protein production. Some of the recent excellent developments in this field include 
production of the correctly folded and post-translationally modified proteins in E. coli like 
human plasma protein tissue plasminogen activator (tPA). This was achieved by engineering 
mutant strains of E. coli that maintain the cytoplasm in a much lesser reduced state and thus are 
impaired in the reduction of glutathione and thioredoxin (Bessette et al., 1999). Adding another 
feather to the cap is the production of the glycosylated proteins, which was achieved by 
engineering the N-linked glycosylation machinery from the bacteria Campylobactor jejuni 
(Wacker et al., 2002). These recent major breakthroughs combined with the traditional 
advantages of bacterial protein production still ranks the E. coli as a scientist’s first choice of 
expression host for the production of recombinant proteins.  
 
 
1.2.2 Advantages and Disadvantages for GPCR production in E.coli 
The main advantages of using E. coli  as a host for expressing recombinant proteins include their 
well-studied life cycle, short doubling time and its easy handling  in the laboratory. Among other 
advantages are the low cost and ability to genetically modify the organism. However, one of the 
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major disadvantages of this expression system is the lack of post-translational modifications on 
expressed eukaryotic proteins. Another disadvantage is its inability to translocate proteins to 
their subcellular destinations, for example the transport of membrane proteins to the membrane. 
The development of a better and more capable E.coli strain is always one of the chief topics of 
research. 
The biggest disadvantage of GPCR production in E. coli stems from the fact that bacteria 
do not express GPCRs and thus lack the machinery for synthesis and translocation of such 
membrane proteins. Moreover, their inability to modify eukaryotic proteins post translation adds 
on to the problem at hand. The most common post-translational modifications in GPCRs include 
glycosylation, phosphorylation and palmitoylation. Although the function of these modifications 
for a given GPCR cannot always be predicted, many GPCRs can function without these 
modifications. In applications like the formation of crystals, post-translational modifications are 
often removed from the recombinant protein provided; it can withstand the removal without 
complete or partial loss of function. This facet of E. coli expression represents an advantage over 
mammalian or cell based systems. The expressed GPCR with the help of fusion partners may be 
targeted to and inserted in the inner bacterial membrane. However, the lipid composition of the 
membrane also contributes to specific requirements by the receptor proteins to be targeted to the 
membrane. Bacterial inner membrane composition is significantly different from that of 
eukaryotic cells, in lacking cholesterol. Also the mammalian membrane is composed of much 
higher levels of phosphatidylserine (PS) which in bacteria is converted to 
phosphatidylethanolamine (PE) by the enzyme phosphatidylserine decarboxylase. Many GPCR 
known so far like the oxytocin receptor, human µ-opoid receptor and the dopamine D1 receptor 
require specific lipid component for optimal functioning (Opekarova and Tanner, 2003). 
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However, in-spite of having disadvantages and differences from the mammalian expression 
system, the E. coli has quite successfully been used for the production of many functionally 
active GPCRs. Yet, it seems to be difficult to generalize rules for the protein engineering and 
setting up expression conditions. Expression levels, even to the extent of all or none, vary 
between receptors which belong to the same GPCR family. Besides, as the mechanisms of action 
of fusion partners are unclear the choice and use of particular fusion partner is a matter of hit and 
trial. Table 1 below summarizes the comparison of advantages and disadvantages of GPCR 
expression  in the E.coli versus baculovirus infected insect cell lines. 
 
Table 1.2 Comparing GPCR expression in Sf9 cells vs E. coli                           
Attribute GPCR  obtained for crystal 
structures
Obtained from E. coli
Easy, fast, cheap Costly time taking insect cell 
growth
Easy, rapid and cheap
Native structure GPCR modified by removing 
terminals, inserting T4 lys
GPCR modification not 
required
Isotopic labelling Not possible Easily possible
Dynamic studies Rigid stabilized structure Can be conducted
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1.2.3 Current methods and developments of GPCR expression and purification 
from E. coli 
GPCR production in the E. coli has developed and evolved with the advent of newer techniques 
which support either membrane targeted or inclusion body directed GPCR expression. These 
methods have their own advantages and disadvantages. The methods can be divided into 
expression of either ‘functional modified GPCR’ or of ‘non-functional, unmodified GPCR’ in 
the E. coli.  
Functionality can be preserved by the membrane targeted expression of the GPCR. The 
fusion of the E. coli periplasmic protein, MBP with the N' terminal of a GPCR results in its 
translocation to the bacterial periplasmic membrane post translation. Several studies have 
reportedly used this approach and successfully conducted the membrane targeted expression of 
GPCRs. These include the rat neurotensin receptor, rat neurokinin 2 receptor, human adenosine 
A2A receptor, human  5HT1a receptor,  M1 and M2 muscarinic acetylcholine receptor,  human 
β2a receptor, and the human cannabinoid CB2 receptor  (Grisshammer, 2009; Weiss and 
Grisshammer, 2002b; Yeliseev et al., 2005).  Newer direction towards the use of alternative 
fusion partners like Mistic, an integral membrane protein expression enhancer, and TarCF, a C-
terminal fragment of the bacterial chemosensory transducer Tar showcases the continued 
developments in this field (Chowdhury et al., 2012). A major setback in this approach is that the 
functional GPCRs within the bacterial periplasmic or inner membrane may lose their functional 
activity upon isolation from the membrane. They may also have altered structural disposition 
when inserted to artificial membrane mimetic environments. Also recombinant GPCR  in E. coli 
membrane may display lesser affinity for its ligands when compared to it being expressed in an 
eukaryotic membrane milieu like transfected mammalian cell lines. 
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A diametrically opposite approach is the expression of ‘non-functional, unmodified GPCR’. In 
this case GPCR is first expressed as inclusion bodies and then refolded in-vitro to its functionally 
active state. This approach depends on the isolation and purification of the GPCR under 
denaturing conditions and then gradually transferring it to milder detergents and membrane  
mimetic environment for structural refolding (Baneres et al., 2011). Several GPCRs have been 
refolded to complete or partial functionality by this approach (Baneres et al., 2003; Baneres et 
al., 2005; Kiefer et al., 1996). However this method is not straightforward and requires 
optimization and trial of every step beginning from expression to purification and most 
importantly refolding to functionality. 
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1.3 CANNABINOID RECEPTOR 2 
1.3.1 The Endocannabinoid System 
The endocannabinoid system includes group of endogenous lipids, enzymes that synthesize and 
degrade such lipids and their cognate receptors (Pertwee, 2006). This system controls in overall 
various physiological processes like mood regulation, immune modulation, pain, memory (Fortin 
and Levine, 2007). The endogenous lipids that make up the endocannabinoid system include 
anandamide (N-arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG). Enzymes 
of the endocannabinoid system include fatty acid amide hydrolase and the monoacylglecerol 
lipase. The Cannabinoid Receptor 1 (CB1) and the Cannabinoid Receptor 2 (CB2) make up the 
receptors of the endocannabinoid system. The binding of endo- or exogenous cannabinoids to 
their cognate receptors (CB1 and CB2) in the CNS and the periphery respectively, lead to 
inhibition of the enzyme adenylase cyclase thereby triggering further intracellular downstream 
signaling. The CB1 and CB2 receptors belong to the Rhodopsin family of GPCRs. In the CNS, 
several endocannabinoids (e.g. 2-AG) are synthesized as a secondary effect of the 
neurotransmitters on the post-synaptic neuron. The effects of these cannabinoids are exerted 
through the CB1 receptor and involve memory, mood regulation, behavior, appetite, etc 
(Hampson and Deadwyler, 1999; Pertwee, 2001). Binding of a cognate ligand to the CB2 
receptor results in immune modulation. In summary, the endocannabinoid system comprises and 
maintains a complicated set of events, interactions and outcomes which regulate diverse 
physiological processes. 
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1.3.2 CB2 Receptor Structure 
The high resolution three dimension (3D) structure of the CB2 receptor has not been resolved, as 
of date. Efforts to purify reconstitute and obtain high resolution structural information of the 
receptor and several attempts to generate the 3D structure of the CB2 by homology modeling or 
ab-initio calculations have been reported.  
The CB2 receptor follows the general structural pattern of Rhodopsin family GPCRs and 
has a glycosylated N'-terminal, seven pass transmembrane domains and an intracellular C'-
terminal tail (Cabral and Griffin-Thomas, 2009; Galiegue et al., 1995a). Overall the CB1 and 
CB2 shares a sequence homology of ~44% based on amino acid composition and the degree of 
similarity in the transmembrane region is ~68% (Cabral and Griffin-Thomas, 2009; Munro et al., 
1993). In an effort to get a general idea of the receptor structure, homology models of the 
receptor were generated by Xie et. al (Xie et al., 2003) and Montero et. al (Montero et al., 2005). 
However, both these studies lacked an adequate number of templates and were constructed only 
on the basis of the structure of the bovine rhodopsin (Palczewski et al., 2000). The receptor 
model arrived at by Xie et. al shows that CB2 consists of structural features typical to Rhodopsin 
family GPCRs. The seven helices are tilted at various angles relative to the plane of the 
membrane with an extensive network of hydrogen bonding among the residues of the 
transmembrane helices. The presence of the conserved D(E)RY motif and the salt bridge 
interaction of the residue Arg 131 (TM3) with the residue Asp 260 (TM6) was observed in the 
model. This salt bridge interaction is the conserved feature of all Rhodopsin family receptors. 
Even though the 3D structure of the CB2 has not been solved yet, a huge impetus to homology 
modeling has been provided by elucidation of the structures of the several other more closely 
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related GPCRs which provide many more templates for more in-depth and higher confidence 
model building.  
Several mutagenesis studies have also been performed which indicate the presence of 
ligand binding and/or stabilizing roles of the various key domains of the CB2 receptor. For 
example, in a study by Zhang et.al the conserved residue Trp 194 was found to mediate the 
process of conformational rearrangement during receptor activation and G protein binding 
(Zhang et al., 2011). Although these studies have provided a huge impetus for CB2 structure 
function research and drug discovery, it is crucial to work towards and determine the high 
resolution structure of the CB2 receptor. 
1.3.3 CB2 Receptor Expression Profile 
The CB2 receptor was cloned and discovered in 1993 by Munro et. al and was initially reported 
to be expressed in macrophages and to marginal levels in the spleen (Munro et al., 1993). The 
gene for the study was cloned from the complimentary DNA (cDNA) of the human 
promyelocytic leukemia line HL60. The cloned DNA was transfected to expression cell lines and 
membrane preparations were used to determine the presence of receptor by testing binding with 
known Cannabinoid ligands. The expression profile of the CB2 receptor is currently well 
established. The presence of the CB2 in immune cells was initially reported by Galiegue et. al 
(Galiegue et al., 1995a). The descending rank order of level of CB2 expression in the immune 
cells follows: B-cells > natural killer cells >> monocytes > polymorphonuclear neutrophil cells > 
T8 cells > T4 cells. CB2 receptor is also expressed in the gastrointestinal system where they 
mediate the process of intestinal immune response. CB2 agonists are routinely used for the 
treatment of several inflammatory diseases like Crohn’s disease and ulcerative colitis (Capasso et 
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al., 2008; Wright et al., 2008). CB2 is also expressed in mast cells where they may mediate 
inflammatory response (Elphick and Egertova, 2001). The Cannabinoid mediated modulation of 
CB2 in mast cells are thought to decrease the noxious stimuli. The mRNA content of the CB2 in 
the spleen is comparable to that of the CB1 in the brain. The respective expression of the CB1 
and the CB2 in the CNS and periphery were believed to be like water tight compartments until 
the discovery of the fact that trace amounts of the CB2 receptor is also found in the brain 
(Onaivi, 2006). However unlike the CB1, the CB2 is mainly expressed in the supporting cells of 
the CNS like the microglia and not in neurons (Cabral et al., 2008; Pertwee, 2006). 
 
1.3.4 Physiological role and therapeutic potential of the CB2 Receptor 
One of the most significant roles of the CB2 receptor is probably in the modulation of 
immunological activities and inflammatory responses in leukocytes (Kaminski, 1998). 
Cannabinoid compounds disrupt leukocyte function by markedly inhibiting the action of 
adenylate cyclase, protein kinase A and decreased DNA binding of the cAMP response element 
binding proteins. These and related effects of the cAMP signaling pathways modulate the 
expression and secretion of cytokines which have deep impact on the immune system (Kaminski, 
1996). Recent studies on the Cannabinoid agonist JWH-015 has revealed that within T cells 
changes in the cAMP levels lead to the phosphorylation of leucocyte receptor tyrosine kinase 
(LRTK) at the conserved Tyr505 which leads to inhibition of T cell receptor signalling. Studies 
are ongoing to determine and use the effects of the Cannabinoid ligands for the treatment of pain, 
particularly neuropathic pain (Cheng and Hitchcock, 2007).  The involvement of the CB2 
receptor in pain can be corroborated with the expression of the CB2 in the spinal cord and the 
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dorsal root ganglion of neuropathic pain animal models (Pertwee, 2008). CB2 receptors also alter 
the maintenance and homing of B cells. These and several more findings clearly indicate the role 
and scope of modulating the CB2 for the treatment of several pathogen related or autoimmune 
disorders. 
The presence of the CB2 in brain microglia has demonstrated possible therapeutic 
application for the treatment of Alzheimer’s disease. The CB2 agonist JWH 015 leads to 
activation of macrophages and removal of beta amyloid plaques (Tolon et al., 2009). The 
accumulation of the plaques leads to the subsequent neurodegeneration (Tiraboschi et al., 2004). 
Overall the CB2 receptor stands as a very promising therapeutic target for several significant 
pathological conditions.  
1.3.5 Overall goal and approaches towards production of functionally active CB2 
Receptor 
In summary, the Cannabinoid Receptor 2 is a very significant therapeutic target (Basu and Dittel, 
2011; Patel et al., 2010). Continued research is uncovering newer roles for the receptor in 
homeostasis and diseases. The lack of selective modulators in the market that can target the CB2 
receptor necessitates CB2 drug discovery efforts. Candidate compounds often either have low 
efficiency or specificity and can target and activate the closely related CB1 receptor which then 
can lead to undesirable effects. High resolution structural information for CB2 will facilitate the 
understanding of the molecular basis of ligand functionality. This will then allow for Structure 
Based Design of potent and selective CB2 receptor modulators. However as discussed in Section 
1.1.2, the challenges towards structure elucidation of CB2, or any GPCR for that matter, arises 
from the lack of purified and functionally active receptor.  Thus in this project, our goal is to 
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develop a method for producing purified, functionally active CB2 receptor within membrane 
mimetic environments (Figure 1.3). For this purpose, we chose to use the E. coli expression 
system as it is the fastest, cheapest expression host that allows for the easy production of 
isotopically labeled protein.   This protein can then be used by NMR and EPR methods to study 
CB2 dynamics with or without ligand activation. The developed methodology and the available 
receptor will then open up newer research both in GPCR expression purification and structural or 
biophysical characterization of the CB2 receptor respectively. To achieve this goal, we plan to 
carry out CB2 receptor expression, purification by two different approaches (Figure 1.3). In the 
first approach, CB2 will be produced as fusion protein with novel fusion partners Mistic and 
TarCF. In the second approach CB2 will be produced as inactive inclusion bodies which will 
then be subjected to refolding trails using different stabilizers or membrane mimetic 
environments to generate functionally active CB2 receptor in vitro. 
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Fusion Protein Approach
Inclusion Body Approach
A
B
C
Functional CB2 receptor in vitro 
 
Figure 1.3. Overall strategic approach for the generation  of  functionally active 
CB2 receptor  in-vitro. 
The overall goal of the project is the generation of functional CB2 receptor in-vitro. 
To carry out CB2 functional expression in the E. coli  inner membrane  CB2 will be 
expressed with fusion partners Mistic and TarCF as N and C terminal fusion partners 
respectively (A).  (B) & (C)  Inclusion body directed approach  using the Trp∆LE and 
the GST tag partners.   
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2.0  EXPRESSION, OPTIMIZATION AND CHARACTERIZATION OF THE 
CANNABINOID RECEPTOR 2 WITH FUSION PARTNERS IN THE E. COLI 
2.1 INTRODUCTION 
2.1.1 Therapeutic significance of CB2 Receptor  
The physiological effects of endogenous and synthetic cannabinoid ligands are mediated by two 
cell surface G-protein coupled receptors cannabinoid receptor subtype 1 (CB1), expressed 
abundantly in the brain and subtype 2 (CB2), expressed mainly in the immune system (Attwood 
and Findlay, 1994). These two receptors, share 68% sequence homology in their transmembrane 
domains and 44% similarity in their overall receptor sequences (Galiegue et al., 1995b; Howlett 
et al., 2002; Munro et al., 1993; Xie et al., 2003).  
After stimulation, the CB2 receptor couples to Gαi to negatively regulate cyclic AMP 
levels by inhibiting adenylase cyclase activity (Bayewitch et al., 1995; Gonsiorek et al., 2000), 
and to the Gβγ domain to enhance MAPK and PI3K activation, ceramide production and 
downstream gene expression (Bouaboula et al., 1999a; Bouaboula et al., 1999b; Bouaboula et al., 
1996). Clinically, modulation of the CB2 signaling exhibits great potential for the treatment of 
inflammatory and autoimmune diseases, cancer, heart and bone disorders as well as 
neurodegenerative disorders (Alexander et al., 2009; Lozano-Ondoua et al., 2010; Martin-
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Moreno et al., 2011; Pacher and Mechoulam, 2011; Zajicek and Apostu, 2011). In addition, CB2 
activation has also shown to have neuroprotective and analgesic effects in animals via unclear 
mechanisms (Anand et al., 2009; Cabral et al., 2008). CB1 is highly expressed in the brain and 
therapeutic modulations of this receptor have resulted in adverse psychotropic side effects 
(Cahill and Ussher, 2007; Kelly et al., 2011). Selective modulation of CB2, however, would be 
able to achieve the desired therapeutic effect without such psychotropic side effects due to no or 
very low expression of CB2 in the central nervous system (CNS). Therefore, the CB2 receptor is 
a significant and desirable target for therapeutic intervention requiring more in-depth information 
regarding the receptor structure and function to design highly selective ligands. However, 
expression levels of CB2 are very low in native tissues, and structure determination of CB2 has 
been impeded due to the inability to produce sufficient amounts of the receptor proteins with 
high homogeneity and natural ligand binding activity. 
 
2.1.2 Efforts towards heterologous GPCR Expression  
Different hosts have been employed to improve the expression levels of GPCRs. Baculovirus-
infected insect cell lines have been used to produce GPCRs  including the cannabinoid receptor 2 
(Nowell et al., 1998), beta 2-adrenergic receptor (Rasmussen et al., 2011; Rasmussen et al., 
2007; Sarramegna et al., 2003b) , chemokine receptor (Kwong et al., 1998) and the A2a 
adenosine receptor (Cherezov et al., 2007; Jaakola et al., 2008); most of which have been 
structurally modified to facilitate receptor stability and crystallization. Yeast cells also provide 
eukaryotic environment for post-translational modification of the exogenous GPCRs (Kim et al., 
2005; Naider et al., 2004). However, compared to mammalian cells, they differ in membrane 
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composition and posttranslational modification  (Sarramegna et al., 2003a). While lacking post-
translational modifications, the bacterial system offers several unbeatable advantages for the 
expression of exogenous proteins: fast, homogeneity in protein production, low cost and ability 
to isotopically label the protein of interest for subsequent NMR studies (Hockney, 1994). 
Previously, E. coli was used in our lab to express CB2 receptor fragments by directing the 
fragment expression to inclusion bodies using the Trp∆LE leader sequence (Xie et al., 2004; 
Zheng et al., 2005). The CB2 receptor fragment produced in E. coli and reconstituted in Brij 58 
showed > 75% preservation of the alpha helical structure (Zhang and Xie, 2008). However, the 
methodology developed in these studies may not be applied to the intact receptor without 
substantial modifications. 
2.1.3 Fusion partners for the functional expression of GPCRs in E. coli 
For heterologous expression of eukaryotic membrane proteins, fusion protein technology in E. 
coli has been successfully applied for numerous proteins (Table 2). For the integral membrane 
protein, neurotensin receptor, the expression level for this receptor was enhanced 40-fold when 
neurotensin was fused to maltose binding protein (MBP) at the N'-terminus and the signal 
peptide sequence Endotoxin B at the C'-terminus (Grisshammer et al., 1993). Related 
methodologies have also been used for the production of the rat neurokinin A receptor 
(Grisshammer et al., 1994) and human adenosine A2a receptor (Weiss and Grisshammer, 2002a). 
In addition, expression of the CB2 receptor by using MBP as an N'-terminal fusion partner and 
Thioredoxin as a C'-terminal fusion partner has also been reported (Berger et al., 2010; Krepkiy 
et al., 2007; Yeliseev et al., 2005).  
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Table 2.1 Fusion tags used for Affinity purification and solubilization of recombinant 
proteins 
Adapted from (Arnau et al., 2011) 
Name of Tag 
Length 
of tag 
(aa) 
Usage conditions 
Chitin-binding domain 52 Can bind to insoluble chitin only 
c-myc 10 Purification based on monoclonal antibodies 
Elastin-like peptides 18 - 320 
Change in temperature can aggregate protein : tag 
removed with intein 
FLAG 8 Purification is Ca2+  dependent and based on mAb 
Glutathione S-
transferase 
201 Glutathione or GST antibody affinity 
HA-tag 9 
Hemagglutinin from  Influenza virus, antibody-based 
purification 
His-tag 5-15 Native or denaturing conditions for purification 
Maltose binding protein 396 Affinity to Amylose 
NusA 495 
Increased solubility in E. coli. Affinity tag needed for 
purification 
Softag1, Softag 3 13, 8 mAb  responsive to Polyol 
S-tag 15 Affinity to S-protein resin 
Streptag II 8 Modified streptavidin; eluted with biotin analog 
T7-tag 11-16 Purification based on monoclonal antibodies 
Thioredoxin 109 Affinity to modified resin 
Xylanase 10A 163 Cellulose based capture; glucose elution 
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Determining the correct fusion partner(s) to optimize GPCR expression is not empirical but 
largely depends on the receptor in question. We have used two new fusion partners Mistic and 
TarCF for CB2 expression. Mistic is an unusual B. subtilis membrane protein (Kefala et al., 
2007; Roosild et al., 2005); TarCF is the C'-terminal fragment of bacterial aspartate 
chemosensory transducer Tar (Antommattei et al., 2004; Krikos et al., 1985). While Mistic and 
TarCF have been routinely used as fusion partners to enhance expression and stabilization of 
proteins, their effects on the expression and stabilization of GPCRs remain obscure and 
unexplored. In the present study, we have evaluated the roles of several fusion partners including 
Mistic, TarCF and TrxA, alone or in combination, to drive the functional expression of the CB2 
receptor in E. coli . To facilitate the fusion protein release and purification, enzymes are used 
routinely (Table 3). Factor Xa/TEV sequences and multi-His tags were introduced into our 
expression construct, Mis-CB2-TarCF. Culture conditions were optimized to determine the 
conditions for maximum fusion protein yield.  
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Table 2.2. Enzyme based methods to remove fusion tags 
Adapted from (Arnau et al., 2011). 
Enzyme Cleavage site Comments 
3C protease ETLFQ*GP Protease removed by Ni-chelating or GSH resin 
Aeromonas 
aminopeptidase 
Exopeptidase 
Cleaves at N-terminal sequentially; Zn2+ required 
for activity; cannot cleave E, D, X-P; acts on M, L 
Aminopeptidase M Exopeptidase Cleaves at N-terminal, cannot cleave X-P 
Carboxypeptidase A Exopeptidase Cleaves  at C-terminal. No cleavage at X-R, P 
Carboxypeptidase B Exopeptidase 
Cleaves at C-terminal; acts on basic amino acids 
(R, K) 
DAPase 
(TAGZyme) 
Exo(di)peptidase 
Cleaves N-terminal; Carries C-terminal His tag for 
removal by subtractive IMAC 
Enterokinase DDDDK* Secondary sites at other basic amino acids 
Factor Xa IDGR* Secondary sites at Gly-Arg 
Granzyme B 
D*X, N*X, 
M*N, S*X 
Nonspecific cleavage activity 
Intein Cleaves self On column cleavage (chitin-beads) 
PreScission LEVLFQ*GP Protease removed by Ni-chelating or GSH resin 
Sortase A LPET*G 
Ca2+-induction of cleavage, requires an additional 
affinity tag for on column removal 
TEV protease EQLYFQ*G His-tag for removal of the protease 
Thrombin LVPR*GS Secondary sites. Biotin labeled for removal 
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2.2 MATERIAL AND METHODS 
2.2.1 Host and Vector Design 
2.2.1.1 Expression Bacteria Strain and Reagents 
The expression bacteria strain E. coli C43(DE3) was purchased from Lucigen (Middleton, WI). 
Strain C43(DE3) contains  no intrinsic plasmids and expresses the T7 polymerase from the 
lacUV5 promoter upon IPTG induction.  In addition, C43(DE3) shows no proteolytic activity 
towards exogenously overexpressed proteins (Miroux and Walker, 1996).  
3H-CP55,940 (specific activity: 88.3 Ci/mmol), CP55,940, WIN55,212-2 and SR144,528 
were obtained from RTI International (Research Triangle Park, NC). Isopropyl-β-D-
thiogalactoside (IPTG), Benzonase nuclease and lysozyme were purchased from EMD 
Chemicals (Gibbstown, NJ). Protease inhibitor cocktail was purchased from Sigma (St. Louis, 
MO). All restriction and DNA modifying enzymes were purchased from New England Biolabs 
(Ipswich, MA).  
 
2.2.1.2 Construction of CB2 receptor expression vectors 
The constructs used in the present study are shown in Figure 2.1. All expression vectors were 
based upon the pET-21a vector backbone. Gene fragment encoding octa histidine tagged Mistic 
(8His-Mistic) was derived from the pMIS3.0E vector via polymerase chain reaction using 
specific primers (For: 5’-ATATACATATGAAACACCACCACC-3’; Rev: 5’-
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AAGCTTACCACTCAGGATCATGTAAT-3’). The forward and reverse primers included the 
restriction sites NdeI and HindIII respectively for subsequent cloning.  The Human cannabinoid 
receptor 2 (CNR2) gene with the Factor Xa sequence (5’-ATTGAGGGACGC-3’) fused at its 5’ 
terminal end (Xa-CB2) was extracted from the pMMHb-Trp∆LE-Xa-CB2 vector using HindIII 
and BamHI sites. The pET-21a-TarCF construct was used as a template. The 8His-Mistic-Xa-
CB2 encoding sequence was cloned upstream of the TarCF gene on the pET-21a-TarCF template 
using NdeI and BamHI sites. A Tobacco Etch Virus (TEV) (sequence 5’-
GAAAACCTATACTTCCAAGGA-3’) protease recognition site was introduced between TarCF 
and CB2 encoding sequences on the expression plasmid pET-21a for higher efficiency and 
specificity of protein cleavage. Similarly, the 8His-Mistic encoding sequence was subcloned into 
the pET-21a-CB2-TrxA template using NdeI and HindIII sites to create the construct (2). 
Constructs (3) and (4) were created by removing either the TarCF sequence (using HindIII and 
XhoI sites) or the 8His-Mistic sequence (using NdeI and AvaI sites) from construct (1), followed 
by subsequent Klenow treatments (or a subsequent Klenow treatment) and intramolecular 
ligation reaction. Double digestion of the constructs with AvaI and HindIII released the CB2 
gene fragment confirming successful cloning. All construct sequences were verified by 
automated DNA sequencing at the University of Pittsburgh Genomics core facility. 
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Figure 2.1. Fusion Partners and Expression Vectors  for CB2 fusion protein production.  
(A)  Left: NMR structure of N′-terminal fusion partner Mistic (PDB:1YGM; golden). Right: 
Fragment (Ile139-Asn184) of crystal structure of TsrCF (PDB:2D4U) which is a homologue 
of the C′-terminal fusion tag TarCF, used in this study. (B) Schematic diagram of human 
CB2 fusion protein constructs. All expression plasmid vectors were constructed on the pET-
21a vector backbone under the control of the T7 promoter. Mistic, the N-terminal fusion tag, 
was separated from CB2 by the Factor Xa sequence while TarCF, C-terminal fusion tag, 
were separated from the CB2 receptor by the TEV sequence. The boxes shown are not drawn 
to scale. TarCF, C-terminal fragment of bacterial aspartate chemosensory transducer Tar; 
TEV, tobacco etch virus sequence; His, Histidine residues. 
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2.2.2 Optimization of receptor production 
2.2.2.1 Culture of E. coli C43(DE3) for protein expression 
Minicultures were inoculated with single colonies from an LB-Ampicillin plate containing 
freshly transformed E. coli C43(DE3). The bacterial cultures were grown overnight in presence 
of Ampicillin (100μg/ml) in a shaker (at 250 rpm) at 37°C. Bacterial maxicultures (1 L) were 
inoculated with the minicultures and shaken at 250 rpm, 37°C until the culture reached an OD600 
of 0.6. Expression of the recombinant CB2 protein was induced with  0.5 mM isopropyl-β-D-
thiogalactoside (IPTG), followed by continuous shaking for another 4 h at 37°C. Cells were 
harvested by centrifugation. After a 50 mM Tris–HCl (pH 8.0) wash, the pellets were stored at -
80°C for further experiments.  
Optimization of culture conditions and IPTG concentration were performed for maximum 
expression of Mistic-CB2-TarCF. Briefly, E. coli C43(DE3) cultures were grown to OD600 of 
0.6, induced with 0.5 mM or 1 mM IPTG and then maintained at 25°C or 30°C for 8, 22, 32, 48 
and 72 h after IPTG induction.  
2.2.2.2 Preparation of bacterial membrane fractions 
The harvested bacterial pellet was washed twice with 0.1 M Tris-HCI (pH 8.0) buffer and 
resuspended in the same buffer containing 20% (w/v) sucrose. The OD600 of the cell suspension 
was adjusted to 10.0. The suspended pellet was incubated at 37°C for 25 minutes in the presence 
of the Protease Inhibitor Cocktail (PIC) (430 μg/ml) and lysozyme (0.5 μl/g ) followed by 
immediate addition of EDTA to a final concentration 10 mM. After a 0.1 M Tris-HCI wash 
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containing 20% sucrose, the pellet was then subjected to osmotic lysis by suspension in cold 
water and sonicated on ice. This suspension was incubated for 1 h with PIC, Benzonase nuclease 
and MgCl2 (10 mM). After a low speed centrifugation (4500 × g, 10 mins), the supernatant was 
subjected to a high speed spin (100,000 × g, 90 mins) at 4°C. The membrane pellet obtained was 
dissolved in Tris-HCI buffer with 20% sucrose and PIC. This was flash frozen and the aliquots 
were stored at -80°C for subsequent use. 
 
2.2.2.3 Detergent Screening 
In an effort to determine the class of detergents that can effectively solubilize Mistic-CB2-TarCF 
from the extracted membrane fraction we used a set of 12 detergents (supplemented in buffers) 
to identify the detergent with the highest membrane protein solubilizing capability.  We used 
DUAL extract membrane protein buffer set (DUAL systems Biotech, Zurich Switzerland) which 
composed of an even representation of 12 detergents of varied physicochemical properties. 
Membrane fractions from E. coli C43(DE3) expressing the Mis-CB2-TarCF were prepared as 
mentioned in 2.2.2.2. Equal amounts of Membrane fractions containing 100ug of total protein 
were aliquot to 12 high centrifugal speed resistant polycarbonate tubes. Membrane preparations 
were spun at 50000xg, 30 mins at 4°C. The supernatant containing the storage buffer was 
completely removed from pelleted membrane preparation. 200ul of detergent buffers (1-12) were 
added following complete solubilization of the pellet. Upon complete solubilization all tubes 
were incubated at RT in a slow orbital shaker. Samples were collected after 4hrs and overnight.  
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2.2.2.4 Detection of CB2 fusion protein expression in E.coli 
Transformed E. coli cell pellets or membrane fractions were analyzed for CB2 expression by 
Coomassie brilliant blue (CBB) staining and Western blot. Cell pellets or membrane fractions 
were lysed in buffer (10 mM Tris-HCl, 10 mM MgCl2, 10% SDS, 430 μg/ml PIC) and sonicated 
briefly. The lysate supernatants were subjected to SDS-PAGE, followed by Coomassie blue 
staining. For Western blot analysis, the lysate supernantant (30 µg) was heat-denatured, 
subjected to 12 % SDS-PAGE, and transferred to polyvinylidene fluoride membrane. Following, 
histidine tagged CB2 receptor were probed with anti-His monoclonal (1:1000, Sigma) and anti-
CB2 polyclonal (1:1000, Cayman Chemicals) primary antibodies. The protein bands were 
detected using Amersham Enhanced Chemiluminescence-Western blotting detection reagents 
(GE Healthcare, Piscataway, NJ). 
 
 
2.2.3 Determination of receptor pharmacological activity in E. coli membrane 
fractions 
2.2.3.1 Saturation binding assay of the fusion protein 
The saturation binding of 3H-CP55,940 to the membrane proteins was performed as described 
previously (Leifert et al., 2009). Briefly, the membrane fractions (20 μg) were incubated with 
increasing concentrations of 3H-CP55,940 (0.01–5 nM) in 96-well plates at 30°C with slow 
shaking for 1 h. The incubation buffer was composed of 50 mM Tris-HCl (pH 7.4), 5 mM 
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MgCl2, 2.5 mM EGTA and 0.1% (w/v) fatty acid free BSA. Ligand was diluted in incubation 
buffer supplemented with 10% dimethyl sulfoxide and 0.4% methyl cellulose. Non-specific 
binding was determined in the presence of 1:1000 unlabeled CP55,940 (5000 nM) in excess. The 
reaction was terminated by rapid filtration through Unifilter GF/B filter plates using a Unifilter 
Cell Harvester (PerkinElmer). After the plate was allowed to dry overnight, 30 µl MicroScint-20 
cocktail (PerkinElmer) was added to each well and the radioactivity was counted by using a Top 
Counter (PerkinElmer). Data from these assays were analysed using GraphPad Prism 5.0 
Software. The difference between total and nonspecific binding equals the receptor specific 
binding. Non-linear regression analysis revealed the receptor density (Bmax) and the equilibrium 
dissociation constant (Kd) values of 3H-CP55, 940 for the CB2 receptor.  
 
2.2.3.2 Competitive ligand displacement assay 
CB2 receptor ligand displacement assay was performed as described previously (Leifert et al., 
2009). The known CB2 ligands CP55, 940 (unlabelled), WIN55, 212-2 and SR144528 were used 
in this displacement assay to test whether the fusion proteins expressed in E. coli C43(DE3) 
exhibited receptor-ligand binding properties. Briefly, non-radioactive (or cold) ligands were 
diluted ( 10-2-103 nM ) in binding buffer [50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 2.5 mM 
EGTA and 0.1% (w/v) fatty acid free BSA], supplemented with 10% dimethyl sulfoxide and 
0.4% methyl cellulose. Each assay plate well contained a total of 200 μl of reaction mixture 
comprised of 20 μg of membrane protein, labeled 3H-CP55,940 ligand at a final concentration of 
4 nM and the unlabeled ligand at its varying dilutions as stated above. Plates were incubated at 
30°C for 1 h with gentle shaking. Reactions were terminated and read as described in the 
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previous section. All assays were performed in triplicate (n=3) and data points represented as 
mean±S.E.M. Bound radioactivity was analyzed for Ki values using non-linear regression 
analysis by GraphPad Prism 5.0 software. 
 
 
 
 
2.3 RESULTS AND DISCUSSION 
2.3.1 Expression of CB2 with fusion partners 
Recombinant CB2 receptor produced in E. coli does not have the ability to translocate to the 
membrane and is devoid of membrane environment. This phenomenon has been proposed to be 
toxic towards the host and lead to misfolded protein aggregation, requiring the isolated protein to 
undergo refolding (Michalke et al., 2010). To enhance membrane protein expression and 
solubility with correct folding, as well as membrane localization of the recombinant GPCRs, 
researchers have employed several approaches including the identification of fusion partners 
linked with GPCRs in E. coli (Korepanova et al., 2005; Zuo et al., 2005). Previous studies have 
shown that MBP or thioredoxin (Trx) can stabilize and improve the expression and solubility of 
foreign fusion proteins in E. coli (Kapust and Waugh, 1999). Furthermore, Trx fusion proteins 
can be folded correctly and express complete biological activity (LaVallie et al., 1993). Mistic, a 
bacterial membrane-associating protein, has been found to enhance expression of eukaryotic 
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membrane proteins at the bacterial membrane (Blain et al., 2010; Kefala et al., 2007; Roosild et 
al., 2005). The chemosensory aspartate receptor, Tar, is a resident membrane protein of the 
bacterial host which is expected to facilitate membrane protein expression (Meir et al., 2010). 
Combining different fusion partners at both ends of a target gene has emerged as a promising 
strategy to facilitate expression and improve the solubility of recombinant proteins (Yeliseev et 
al., 2005).  However, application of the fusion tags Mistic and TarCF for the expression of 
GPCRs in E. coli has not been investigated previously. For the first time, we report in this study 
the use of different fusion partner combinations (Mistic, TarCF and TrxA) for the functional 
expression of the recombinant CB2 receptor in E. coli C43(DE3). We show here, that the fusion 
protein Mistic-CB2-TarCF is overexpressed by E. coli and localized to the bacterial membrane 
with ligand binding properties comparable to those on mammalian cells. 
 
2.3.2 Expression of Cannabinoid receptor 2 fusion protein in E. coli 
E. coli C43(DE3) cells were transformed respectively with the fusion constructs shown in Figure 
2.1. Expression of the recombinant fusion proteins were detected by Western blot or Commassie 
Blue staining. Since all constructs contain a multi-histidine tag, we used either anti-His or anti-
CB2 antibody to detect expression of the CB2 fusion protein. As shown in Figure 2.2A, Mistic 
and TarCF alone failed to boost the CB2 gene expression. Only when both partners were linked 
to CB2 in the proper order did the fusion protein expression increase dramatically. In addition, 
fusion protein expression was also observed with the Mistic-CB2-TrxA construct at a 
comparable expression level with that of the Mistic-CB2-TarCF (Appendix B; Figure 4.15). 
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However, the construct Mistic-CB2-TarCF was used for further optimization due to its novel 
combination of fusion partners and prominent expression levels of recombinant fusion protein. 
Next, we investigated whether the expressed CB2 fusion protein possessed membrane 
affinity or localized to the E. coli membrane. Coomassie staining of the membrane enriched 
fractions revealed a prominent band at MW ~ 86 kDa for the fusion protein Mistic-CB2-TarCF 
while no bands were detected for the fusion proteins that carried either the Mistic or TarCF tag 
individually (Fig. 2.2B). Importantly, the membrane enriched fractions exhibited the same 
expression pattern as the whole E. coli cell lysates indicating that all or the majority of CB2 
fused protein driven by the two partners could localize or integrate into the E. coli membrane. 
Our data suggests that combination of the two tags (Mistic and TarCF) may contribute 
synergistic effects on the CB2 protein expression compared to either tag used alone. Our data 
also show that membrane fractions contain concentrated CB2 fusion protein compared to the 
whole cell lysate, indicating that most of the fusion protein is localized within the bacterial 
membrane. This is in accordance with previous studies where the effects of Mistic and other 
bacterial membrane resident protein to stabilize GPCR expression has been demonstrated 
(Baneyx, 1999; Freigassner et al., 2009; Kefala et al., 2007).  
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Figure 2.2. Expression of the CB2 receptor fusion protein 
(A) Coomassie Brilliant Blue staining on the SDS–PAGE of extracted membrane 
fractions. The expected MW for the respective fusion proteins are as follows – Lane 1: 
Mistic– CB2–TarCF (86 kDa); Lane 2: Mistic–CB2 (71 kDa); Lane 3: CB2–TarCF (55 
kDa). Red arrow show the corresponding Mistic– CB2–TarCF fusion protein expression. 
M: protein marker. Care was taken to normalize the amount of E. coli C43(DE3) 
membrane fraction sample loaded on the gel. (B) Representative immunoblot of His-
tagged CB2 fusion protein detected in E. coli C43(DE3) membrane fractions using anti-
His antibody. Membrane fractions loaded from left are Lane 1: Mistic–CB2–TarCF; 
Lane 2: Mistic–CB2; Lane 3: CB2–TarCF.  
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In absence of induction with IPTG, there was no expression of the fusion protein. However, after 
induction with IPTG, the fusion protein level increased significantly in a time-dependent manner 
(Fig. 2.3), suggesting that the expression cassette is under the tight control of the lac operon and 
T7/lac promoter and lacI gene in the pET21a. Control of recombinant protein expression under 
the tight regulation is necessary to avoid toxicity of protein expression to the host and ensure 
sufficient biomass of viable E. coli that would be available for membrane protein expression 
after induction.  
To determine the time point of maximum receptor production, IPTG-induced cells were 
harvested at different time intervals from 1-8 hours. Whole cell lysates were analyzed by 
Western blot using mouse anti-His (1:1000 dilution) and rabbit anti-CB2 antibodies (1:500 
dilution). As shown in Figure 2.3A, CB2 fusion protein expression levels steadily increased and 
reached maxima at 3-4 hours, followed by significantly reduced expression. The steady decrease 
in the expression level is due to the increased proteolytic cleavage of the produced protein. Thus, 
from this experiment we can conclude that the expression level of the fusion protein peaked 
during culture at 37°C for 3-4 hours after IPTG induction. Since IPTG induction at lower 
temperature was previously reported to improve the exogenous protein production and correct 
folding (Freigassner et al., 2009), we  optimized the culture conditions by combining different 
IPTG concentrations (0.5 mM and 1 mM), culture temperature and time. We found that the 
expression levels of the fusion protein Mistic-CB2-TarCF are weakly detected during culture 
period (2 to 8 h) at 22°C (data not shown). The fusion protein expression at 30°C was not distinct 
from the regular 37°C culture condition (Fig. 2.3B). However, once the transformed cultured 
underwent IPTG induction (1 mM) at 25°C for 8 h, the fusion protein levels were significantly 
increased 2-fold of that of regular conditions (Fig. 2.3B). Overall, 0.5 mM IPTG used for 
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inducing protein expression resulted in lower amounts of fusion protein than 1 mM—especially 
for the conditions of culture temperatures at 25 or 30°C (data not shown).   
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Figure 2.3 Optimization of conditions for fusion protein expression in E. coli. 
(A) Cells transformed with Mistic–CB2–TarCF were grown for the indicated hours 
after induction with IPTG (0.5 mM). Expression levels of fusion protein Mistic–
CB2–TarCF tagged with poly-histidine were detected by Western blot with anti-
CB2 or anti-His antibody. Control group (0 hrs) represents no IPTG induction. (B) 
Optimization of Mistic–CB2–TarCF fusion protein production in E coli. Different 
combinations of the parameters (IPTG, culture temperature and time) were tested 
and one representative is shown. 
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2.3.3 Receptor Saturation Binding Assay 
pET-21a-Mistic-CB2-TarCF transformed E. coli membranes were subjected to a saturation 
binding assay to determine receptor saturation with increasing concentrations of 3H-CP55,940. 
pET-21a-TarCF transformed E. coli membranes were used as the negative control. For the 
membrane proteins derived from Mistic-CB2-TarCF transformed E. coli , the maximal receptor 
density (Bmax) and dissociation constant (Kd) of 3H-CP55,940 for specific binding sites were 
928.8 ± 117.6 fmol/mg protein and 3.04 ± 0.69 nM, respectively (Figure 2.4A). Membrane 
fractions clearly showed CB2 receptor binding characterization by the abundance of binding sites 
recognized by agonist 3H-CP55,940. For the negative control, however, no difference was 
observed between specific and nonspecific binding (Figure 2.4B), indicating that the 
overwhelming majority of the total binding was contributed by the nonspecific binding. This 
confirms the absence of CB2 receptor on pET-21a-TarCF transformed E. coli membranes. A 
comparison of the specific saturation binding profile of Mistic-CB2-TarCF and the negative 
control CB2-TarCF is represented in the Appendix A Figure 4.9. The comparative plot highlights 
the difference of Bmax values. 
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Figure 2.4 Saturation binding assay of the membrane fractions 
Saturation binding assay was performed with membrane fractions by increasing the 
concentration of agonist, 3H CP 55940 using a fixed amount of  target protein. A 
1:1000 excess of cold CP 55940 was added in the reaction mixture to account for non 
specific binding. Total (○) and non-specific (■) binding was measured and the 
deduced specific binding saturation isotherm (▲) was obtained as the difference 
between total and nonspecific binding. (A) Mistic–CB2–TarCF; (B) pET 21-TarCF 
(negative control). Assay was performed in triplicate (n = 3). Data presented as mean 
± SEM. (C) Chemical structure of the non-classical Cannabinoid receptor agonist, 3H 
CP 55940.  
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2.3.4 Receptor Competitive Binding Assay 
The conformational state of a receptor protein determines the functional state of a receptor. High 
affinity binding between a ligand and its receptors is often physiologically important when a 
portion of the binding energy can be used to cause a conformational change in the receptor, 
resulting in altered downstream signaling pathways. In the present study, to confirm whether the 
expressed fusion proteins from the E. coli exhibit functional binding activity, we used  well-
known CB2 ligands to probe the interactions of these ligands with their cognate binding sites on 
the CB2 enriched membrane fractions (competitive binding assay), by quantifying the 
equilibrium dissociation constant (Ki). By using 10 µg of membrane fractions of Mistic-CB2-
TarCF fusion protein in the binding assay, the Ki values for these ligands were well consistent 
with previous reports using the CB2 from mammalian cells: CP 55,940 (Ki = 1.43 nM), SR 
144528 (Ki = 2.02 nM)  and WIN 55212-2 (Ki = 0.13 nM). These results (Figure 2.5) indicate 
that the ligand binding domain of the CB2 receptor in the fusion protein is not perturbed by the 
physical presence of its neighboring fusion partners Mistic and TarCF.  
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Figure 2.5 Competitive ligand displacement assay of the membrane fraction. 
Upper Panel : Chemical structures of (A) non-classical Cannabinoid receptor agonist, 
3H CP 55940  (B) receptor inverse agonist SR144528 and (C) receptor agonist 
WIN55212-2.  Lower Panel: Competitive displacement of the 3H-CP55,940 was 
obtained by using an increased amount of cold ligands. Binding profile of  (D) 
CP55,940 (unlabelled), Ki = 1.43 nM; (E)  SR144,528, Ki = 2.02 nM; and (F) 
WIN55,212–2, Ki  = 0.13 nM. Assay was performed in triplicate (n = 3). Data 
represented as mean ± SEM. 
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2.3.5 Detergent Extraction of Mis-CB2-TarCF 
The capability of a particular detergent to extract fusion protein from the membrane depends on 
the combination of several physicochemical properties. These include the overall hydrophobicity 
of the Membrane protein (or its fusion construct), length of the fatty acyl chain and the size of 
the polar head group. In an effort to compare the extraction efficiencies of different classes of 
detergents, we used Ionic, Non-Ionic, Zwitter Ionic and Alkylsaccharide detergents to extract 
Mis-CB2-TarCF from membrane fractions. As shown in Figure 2.6, alkylsaccharides and zwitter 
ionic class of detergents showed a higher efficiency of extraction. Results clearly indicate the 
presence of a much heavier band for the Mis-CB2-TarCF at ~85kDa for these detergent classes 
with slightly better extraction efficiency for the alkylsaccharides. Interestingly these detergents 
also show increased extraction efficiency for the contaminant protein observed at ~60kDa. This 
observation is consistent with previous attempts for detergent extractions of membrane bound 
GPCRs (Yeliseev et al., 2007; Yeliseev et al., 2005).  
We understand that the targeting of fusion partners to the bacterial membrane is critical to 
the conformational stability of the expressed CB2 protein. The possible role of the fusion 
partners for the overexpression and stabilization the CB2 protein is illustrated schematically 
(Figure 2.7) for easy comprehension. Two different dispositions of the TarCF can possibly lead 
to the stabilization of the fusion construct – one with the alpha helical segment of the TarCF 
extending into the cytosol (Figure 2.7A) and the other to the transmembrane region (Figure 
2.7B).  In this putative model, the CB2 receptor structure was adapted from the 3D CB2 model 
reported previously by Xie et al. [5], while the structure of Mistic and Tsr (structurally related to 
Tar) were determined by NMR (PDB:1YGM) [40] and cryo-electron microscopy [55] studies, 
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respectively. However, confirming the putative model will be subject to further biophysical 
studies. 
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Figure 2.6. Detergent screening for extraction of Mis-CB2-TarCF 
Screening for solubilization was done using a representative set of 12 detergents which 
vary widely in their physicochemical properties - Ionic, Non-ionic, Zwitterioninc or 
alkylsaccharaides by nature (DUAL extract membrane protein buffer kit, Dual systems 
Biotech). (A) and (B) Coomassie Briliant Blue staining of SDS-PAGE of solubilized 
membrane fractions of E. coli C43(DE3) transformed with Mistic-CB2-TarCF. (C) 
Chemical structure of alkylsaccharides that solubilized the extracted membrane most 
effectively (highlighted in red on PAGE). 
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Figure 2.7.  Putative models of the Mistic-CB2-TarCF within the E.coli inner 
membrane 
Model showing two possible modes of orientation of the TarCF in the Mis-CB2-
TarCF,which may lead  to a stabilized structure of the fusion protein (A) Mistic-CB2-
TarCF located within the lipidic bacterial inner membrane with the C′-terminally 
fused TarCF tag extending into the cytosol. (B) TarCF fragment can fold onto itself 
and extend into the lipid bilayer of the E. coli inner membrane. Hydrogen bonding 
interactions stabilizing the alpha helix would be more stable in the lipid environment 
(low dielectric constant). 
A
B
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2.4 CONCLUSION  
The Mistic-CB2-TarCF expression construct can produce functional CB2 receptor in E. coli C43 
(DE3) membrane. We observed several novel attributes of the fusion partners Mistic and TarCF.  
Mistic and TarCF can together boost the expression of CB2 to a much higher level compared to 
Mistic or TarCF alone. Using the tag partners in combination it was observed that majority of the 
fusion protein translocated to the bacterial inner membrane. Further we observed a saturable 
binding pattern of the CB2 ligand, 3H – CP55940 which is a clear indication of the receptor 
mediated binding event. Competitive Ligand Binding was observed with different subclasses of 
CB2 ligands. All these data taken together indicate that functional CB2 receptor can be produced 
in the bacterial membrane.  Despite the functionality of the membrane bound CB2, the 
expression level of the protein in bacteria is very low. This is in accordance with our 
observations that SDS PAGE CBB staining of the whole cell lysates from bacteria reveal little or 
no expression of the protein, whereas when enriched membrane fractions were used, moderate 
expressions levels were noted by SDS-PAGE. This posed as a huge roadblock towards moving 
in the direction of extraction and purification of the expressed protein. In our small scale 
detergent screening, we observed that Mistic-CB2-TarCF bands can be extracted with 
alkylsaccharide class of detergents. However we used enriched membrane fractions as starting 
material.  Very less starting material was obtained at the start of the chromatographic processes.  
In our pilot scale chromatographic steps we observed very low elution of the specific protein; 
which is probably due to the presence of small amounts of the protein of interest in the starting 
load material and also the low capture efficiency of the protein in the presence of detergents. 
With these reasons combined we determined that using an expression system with much higher 
yields of CB2 would allow moving forward for purification and characterization steps.  Hence 
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we moved to the approach of inclusion body directed expression of the CB2, which will be 
discussed in the following chapter. 
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3.0  EXPRESSION AND PURIFICATION OF THE CB2 FROM INCLUSION BODIES 
3.1 INTRODUCTION 
3.1.1 Inclusion Bodies 
Inclusion bodies (IBs) are protein aggregates, about 0.5-1.3μm in diameter, formed in the 
cytoplasm or sometimes in the periplasm due to over expression of a protein in bacteria.  
Combination of several factors result in the formation of these highly dense (~1.3mg/ml) 
aggregates that are predominantly amorphous in character.  The threshold concentration of the 
protein that is believed to lead to inclusion body formation is ~2% of the total cellular protein. 
Proteins having disulfide bonds are usually prone to form inclusion bodies since the formation of 
disulfide bonds is inhibited by the reducing cytoplasmic environment. Also the formation of 
inclusion bodies are more pronounced when the protein of interest is hydrophobic. The 
concentration of a protein of interest within the inclusion bodies is very high. Inclusion bodies 
can be easily isolated following cell disruption. In composition the inclusion bodies generally 
have a highly hydrated formation. 
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3.1.2 Advantages and disadvantages of GPCR expression as inclusion bodies (IBs) 
The expression of GPCRs as inclusion bodies in the E. coli results from the incapability of the 
bacterium to handle and process the expressed recombinant protein. Formation of inclusion 
bodies in a cell is undesirable, yet there are some advantages associated with the formation and 
localization as IBs in E. coli. The formation of IBs can be determined as the presence of 
refractive particles in the cytoplasm (Margreiter et al., 2008). One of the main advantages of 
producing GPCRs, or for that matter, any heterologous gene product as IBs is that they are 
mostly enriched with the recombinant protein (99%). However the IBs may also contain 
chaperones and membrane fragments. The IBs self-associate to form tight clusters, thereby 
masking the proteolytic sites on the proteins. Hence IBs are generally refractory to proteolytic 
cleavage. They are usually mechanically very stable and thus can be isolated and enriched from 
the cell preparations by centrifugation. For receptors like mouse Cannabinoid Receptor 
1(muCB1), human Parathyroid Hormone Receptor 1(huPTHR1)(Michalke et al., 2010), 
Chemokine receptor (Park et al., 2006) the yield of membrane protein receptors would increase 
manifolds if expressed as inclusion bodies. The applicability and the success of the method to 
produce and generate “native like” GPCR depends on the combined success and method 
development of firstly the IB directed expression, purification and secondly the development and 
availability of methods to refold the obtained IBs. These challenges will be discussed in the 
following sections. 
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3.1.3 Current  methods for Inclusion Body directed expression 
Once a protein is expressed in large quantities as insoluble inclusion bodies, it can then be 
solubilized and refolded to gain functionality. The method to produce relatively soluble protein 
from these insoluble aggregates has had a significant commercial consequence when it was used 
to produce therapeutic proteins and peptides (Marston, 1986). The composition of efficient in-
vitro refolding environment are available in the REFOLD database 
(www.refold.med.monash.edu.au) (Chow et al., 2006). Refolding strategies are generally based 
on the use of strong denaturing detergents to extract the protein from the IBs and then 
successively exchange them with milder detergents to allow them to refold (Misawa and 
Kumagai, 1999). The necessity of the fusion partner for directing the expression of some proteins 
as IBs is counterintuitive. Expressed protein in the bacteria exist in the equilibrium of properly 
folded, partially folded and aggregates or inclusion bodies and are all subjected to the actions of 
chaperons and proteases (Villaverde and Carrio, 2003). Fractions which exist in the partially 
folded state are much more susceptible to proteolytic degradation hence a fusion partner 
attachment is provided to minimize protein yield loss in cases where the protein will not be 
expressed in the soluble fraction. (Hwang et al., 2013). Ideal fusion partners for the generation of 
IBs typically include proteins with an overall hydrophobicity and the tendency to form beta 
sheets (Fernandez-Escamilla et al., 2004). Some of the most common fusion partners are the 
Ketosteroid isomerase (KSI), EDDIE, PagP, Trp∆LE and GST. 
The KSI fusion partner is a 14 kDa protein (Kamerlin et al., 2010) that is available in the 
pET13b expression vector from Novagen. The protein is extremely hydrophobic and has a strong 
tendency to accumulate with the fusion partner as inclusion bodies. The KSI fusion system has 
been used well for the expression of the antimicrobial peptides which are rendered inactive in 
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their IB state. Antimicrobial peptides have also been expressed using several other fusion 
partners e.g. the truncated E. coli PurF fragment (Lee et al., 2000) and the histone fold fragment 
of the human transcription factor TAF12 (Vidovic et al., 2009). The NPRO derived from the N- 
terminal auto protease, is derived from the classical swine fever virus (CSFV) and is also known 
as EDDIE (Achmuller et al., 2007). The NPRO   tagged protein is expressed both as inclusion 
bodies and as soluble proteins within the E. coli. Insoluble, tagged fusion was dissolved in 
Guanidine HCl and was then dialyzed in refolding media to remove the GuHCl. The NPRO is 
cleaved off and removed while in the refolding process. This is an example where following 
inclusion body directed expression the tag can be removed enzymatically without any 
requirement for chemical cleavage.  
Another recently developed method to have IB directed expression  of recombinant 
proteins involve using the PagP expression system (Hwang et al., 2012). PagP is a bacterial 
membrane protein which localizes itself in the outer membrane of Gram negative bacteria. It is 
structurally similar to many bacterial outer membrane proteins in having a beta-barrel with the 
hydrophobic amino acids facing the lipids and the hydrophilic residues making up the 
hydrophilic inner core. Surprisingly, in spite of the high content of beta-barrel structure, PagP is 
not very hydrophobic making it easier for solubilization. Mutations that excise the membrane 
localization signal from this protein makes it an ideal choice for the expression of this protein as 
a fusion partner for IB directed expression (Booth and Curran, 1999).  
The Trp∆LE expression system is an example of a fusion partner developed early on and 
leads strongly towards IB directed expression of the fusion partner (Landick et al., 1985). The 
bacterial Trp operon consists of a leader sequence- TrpL composed of a 14 amino acid leader 
sequence (MKAIFVLKGWWRTS) followed by a stop codon. A large deletion was made from 
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that encompassed a portion of the  TrpL leader sequence and the start of the first protein coding 
sequence TrpE. This resulted in the formation of the fused polypeptide known as Trp∆LE 
(Trp∆LE). The Trp∆LE is composed of 17 amino acid residues and includes the N-terminal end 
of the Trp∆LEader sequence fused in frame with the carboxy terminal fragment of TrpE. A 
remarkable increase in the amount of protein expression was noticeable when the Trp∆LE was 
fused to insulin, somtostatin and TGF-α (Derynck et al., 1984). The application of the Trp∆LE as 
a fusion tag has become significantly widespread and has been used for the production of several 
small peptides and also some small membrane proteins (Cook et al., 2011). The impetus to use 
the Trp∆LE as a fusion partner in our study was corroborated by the recent development of 
methods to refold GPCRs from IBs (Michalke et al., 2010).  
The Glutathione S Transferase is a 26 kDa protein derived from the Schistosoma 
japonicum and has been frequently used for a one step purification of many different fusion 
proteins (Smith and Johnson, 1988). The purification is conducted by the binding of the GST to 
immobilized glutathione which can then be released by the addition of 10mM of reduced 
glutathione. The advantages of having the GST fusion partner are more than just purification. 
The GST tag allows for enzymatic detection of the protein purified protein and may protect the 
protein from the proteolytic digestion by sequestering the GST tagged proteins as 
dimers/oligomers. The GST tag may allow for the soluble expression of proteins however GST 
tag is considered to be a poor “solubility enhancer” as tagging with the GST partner may lead to 
a combination of soluble, insoluble or partially soluble proteins. GST tagged protein purification 
is a matter of consideration for the extraction and purification of inclusion bodies particularly 
when denaturing conditions are employed. Denaturing conditions would result in conformational 
disruption of the GST and it will not be able to bind the immobilized glutathione. However mild 
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denaturing conditions can be used with the GST tag. This has been a cause of concern which has 
been exploited in the expression and purification of the CB2 receptor, in the present study. The 
GST fusion tag is bulky and is generally needs to be removed for proper folding, activity and 
crystallization of the fused partner protein. Most expression vectors like pGEX expression vector 
(GE Healthcare) contains the gene encoding a protease cleavage site e.g. Thrombin, Factor Xa or 
TEV (PreScission) proteases. The GST tagged protein after cleavage can be removed from the 
reaction mixture by subtractive IMAC using a charged GSTrap column. 
 
3.1.4 Current methods for solubilization and purification of Inclusion Bodies 
Solubilization of the hydrophobic IB by denaturant or detergents and the removal of the 
expression/ fusion partners by proteases are the essential steps towards the purification and 
refolding steps. The procedure and the use of a few different denaturing agents will be discussed 
in this section. Although we have implemented milder detergents in our study, this section will 
have a brief overview of all the possible denaturant/ detergent solubilization methods available. 
The discussions about the particular solubilizing method implemented for the CB2 in our present 
study (using SDS and Sarkosyl) is mentioned methodologies section 3.2. In general, due to the 
hydrophobic nature of inclusion bodies, solubilization is the key step for the isolation of the 
inclusion bodies. The solubilizing detergent may be used in the subsequent steps of purification 
and protease cleavage. Guanidine Hydrochloride at 6 Molar concentration is often a good choice 
as a denaturant since it does not lead to chemical modifications on the amino acid residues in the 
protein. It can also be used during IMAC purification.  However it is not compatible with SDS-
PAGE. On the other hand, urea has the advantages of being cheaper and compatible with SDS-
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PAGE. Urea has its own disadvantages since it can form isocyanate ions on long term storage 
which can carbamylate the amino groups in a protein. 
Following solubilization, the protein of interest is available in the liquid phase for 
purification. In general the first step involves purifying the solubilized protein by exploiting the 
affinity of the fused tag to its ligand that is immobilized on a purification column. This step 
concentrates the protein of interest and isolates it to high degree of homogeneity upto as much as 
90-95%. Commonly used expression tags include polyhistidine, GST, MBP. The Immobilized 
Metal Affinity Chromatography (IMAC) – which includes Ni2+  is one of the best choices at this 
step for several reasons. Firstly the polyhistidine tag is usually made up of only six Histidine 
residues and generally does not interfere with the protein’s structure and /or activity when left 
fused (not removed from the protein by chemical/ enzymatic cleavage) even after purification or 
renaturation. Secondly, the tag solely works on the interaction of the charged divalent cation of 
nickel and localized electron pair on His residue (Ni2+-- Histidine interaction).  Hence it is 
compatible with most of the denaturing conditions like Urea, Guanidine Hydrochloride and upto 
1% SDS. Other commonly used tags are the Glutathine-S-transferase (GST) or the Maltose 
Binding protein (MBP) that rely on the secondary structure of the protein tag and also  have 
greater conformation dependent binding compared to 6X Histidine. However these tags can be 
used in a milder detergent containing buffer. 
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3.2 MATERIAL AND METHODS 
3.2.1 Expression  and purification of CB2 with the Trp∆LE partner 
3.2.1.1 Expression bacteria strain and Reagents 
The expression bacteria strain E. coli C43(DE3) competent cells was purchased from New 
England Biolabs (Ipswitch, MA).  The base vector, pMMHb plasmid was a kind gift from Dr. 
Stanley Opella at the University of California San Diego. Isopropyl-β-D-thiogalactoside (IPTG), 
benzonase nuclease and lysozyme were purchased from EMD Chemicals (Gibbstown, NJ). 
Phenylmethylsulfonyl fluoride (PMSF) was purchased from Sigma Aldrich (St. Louis, MO). 
Enzyme Factor Xa was obtained from New England Biolabs (Ipswitch, MA). AKTA machines 
and chromatographic media were obtained from GE Healthcare. Detergents Triton X-100 was 
purchased from Pierce, Dodecyl- β-D-maltoside (DDM) and octyl glucoside were purchased 
from Affymetrix. All general chemicals (like SDS, Tris-HCl and salts) were obtained from 
Fisher Scientific (Pittsburgh, PA). Antibodies to His tag and CB2 were purchased from Santa 
Cruz Biotechnologies and Thermo Fisher respectively.  
3.2.1.2  Expression Vector design and construction 
The expression vector for the Trp∆LE fusion expression of the CB2, pMMHb-Trp∆LE -9His–
Xa-CB2 was previously constructed in our laboratory. Construction of the expression vector and 
expression of CB2 receptor transmembrane fragments are described in several publications (Xie 
et al., 2004; Zheng et al., 2006; Zheng et al., 2005).  The construct (Figure 3.1A) was designed to 
separate the CB2 from the Trp∆LE leader by the Factor Xa enzymatic cleavage site. Verification 
of the expression vector was conducted by double digestion of the parent gene with HindIII and 
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BamHI to release the CB2 gene fragment. The released product was gel purified and sequence 
verified as CB2 receptor cDNA. All sequences were verified by automated DNA sequencing at 
the University of Pittsburgh Genomics core facility. 
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Figure 3.1. Expression vectors for inclusion body directed expression of the CB2 
receptor 
 
Schematic diagram of human CB2 fusion protein constructs. Expression plasmid 
vectors were constructed on the pET-21a vector backbone under the control of the T7 
or tac promoter. The CB2 receptor was fused to either Trp∆LE or a GST tag and was 
separated by Factor Xa or Thrombin cleavage sites respectively. Both the constructs 
carried either a  N′-terminal (9) His tag or a C′-terminal (6) His tag.   The boxes shown 
are not drawn to scale. Trp∆LE - Trp∆LE fusion leader,  ; GST, Glutathione-S-
Transferase; His, Histidine residues. 
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3.2.1.3 Expression and purification of the Trp∆LE-9His-Xa-CB2 
 
Small scale expression of Trp∆LE-9His-Xa-CB2 
Minicultures (5ml) were inoculated with single colonies from an LB-Ampicillin plate containing 
E. coli C43(DE3) freshly transformed with the expression construct pMMHb-TrpΔLE-9His-Xa-
CB2. Midicultures (25ml) were inoculated with the minicultures and grown until the culture 
reached an OD600 of 0.7. All bacterial cultures were inoculated in a 1:100 ratio (v/v) of the 
(saturated culture) : (fresh media) in presence of Ampicillin (100 µg/ml) and grown in a shaker 
(at 250 rpm) at 370C. Expression of the recombinant CB2 protein was induced with 1 mM 
isopropyl-β -D-thiogalactoside (IPTG), followed by continuous shaking for about another 3 hrs 
at 37oC. Cells were harvested by centrifugation. 
 
Preparation, enrichment and solubilization of Inclusion bodies 
Cell pellets were resuspended in 100 ml lysis buffer (0.1 M Tris–HCl, pH 7.5; 10 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF) 
supplemented with Lysozyme and Benzonase nuclease). The slurry was tip sonicated for 5 mins 
under low or medium output control (3-8, Fischer Scientific Dismembrator Sonifier) with the 
sample on ice and followed by centrifugation at 48,000xg for 20 mins at 4°C. Supernatant was 
discarded. Pellets from the spin were washed twice in 0.1 M Tris–HCl, pH 7.5; 10 mM EDTA 
and 1 M NaCl. The slurry was resuspended in 40 ml of extraction buffer (0.1 M Tris–HCl, 
pH8.0; 10 mM sodium dodecyl sulfate (SDS), 100 mM dithiothreitol (DTT), and 1 mM EDTA 
overnight at room temperature. Solubilized proteins were separated from the insoluble material 
by centrifugation at 48,000g for 20 min at room temperature and dialyzed against 0.1 M sodium 
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phosphate (pH 8.0) and 10 mM SDS. The solubilized enriched IB preparation was tested for the 
presence of the Trp∆LE-His9-Xa-CB2 fusion protein by Western Blotting. Briefly, the load 
material was separated on an 8% SDS-PAGE gel, transferred to a PVDF membrane and the blot 
was probed with Anti His and Anti CB2 antibodies.  
 
Large scale preparative pH gradient purification of Trp∆LE-9His-Xa-CB2 
For a larger scale purification method development, cultures from about 4 liters were pelleted 
and were processed as described in the previous section. The solubilized enriched inclusion body 
preparation was subjected to extensive dialysis against loading buffer (0.1 M sodium phosphate, 
10mM SDS, pH 8.0). At least two changes of the dialysis buffer were done followed by a high 
speed spin and filtration of the loading material. Load material was loaded onto a 10-ml Ni2+ 
affinity column (His Trap GE Healthcare) pre-equilibrated with loading buffer. After five 
successive column volume (CV) washes with the loading buffer at pH 8.0 and pH 7.0, the 
receptor was eluted in the same buffer at pH 6.0. The eluent fractions were analyzed by SDS-
PAGE Coomassie Brilliant Blue Staining. Fractions containing our protein of interest were 
pooled together for further purification. A cation exchange chromatography on a SP FF column 
(GE Healthcare) was used for this. The column was equilibrated with 0.1M Tris-HCl, 10mM 
SDS, 1M NaCl to generate a charged matrix. The collected material was loaded onto the pre-
equilibrated and charged SP FF column. The eluent from the ion exchange chromatography was 
concentrated upto a maximum of 10mg/ml in a volume of ~5ml and was loaded into a Hi Load 
Superdex column pre-equilibrated with 20mM Tris-HCl at pH 8.0. This buffer condition is 
suitable for the enzymatic cleavage of the Factor Xa enzyme. Peak corresponding to the protein 
of interest was collected and dialyzed against cleavage buffer (20mM Tris-HCl, pH 8.0).  
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Factor Xa Cleavage 
The manufacturer recommendations state that 1µg of Factor Xa enzyme can cleave 50µg of the 
recombinant protein at 20mM Tris-HCl (pH-8.0) supplemented with 100mM NaCl and 2mM 
CaCl2. Referring to the recommended concentration of Factor Xa as 1U (enzyme unit), reactions 
were set up over a range of concentrations (0U, 0.02U, 0.5U and 1.0U) of Factor Xa enzyme. 
Reactions were incubated by mixing the recombinant protein with the Factor Xa. Aliquots (equal 
volume containing 50µg of the recombinant protein – corrected for the dilution caused by Factor 
Xa) were collected at regular intervals of 3, 6, 9 and 16 (overnight) hours. Negative controls 
were maintained by collecting the recombinant protein diluted in the cleavage buffer without 
factor Xa at all the time points to account for any self cleavage.  
 
3.2.2 Expression and purification of  CB2 with the GST partner  
3.2.2.1 Expression Bacteria strain and reagents 
The expression bacteria strain E. coli BL21 competent cells was purchased from New England 
Biolabs (Ipswitch, MA).  The base vector, pGEX 2T-M plasmid was obtained from Addgene 
(Addgene plasmid # 1128). All PCR and DNA modifying enzymes were purchased from New 
England Biolabs (Ipswitch, MA). Isopropyl-β-D-thiogalactoside (IPTG), benzonase nuclease and 
lysozyme were purchased from EMD Chemicals (Gibbstown, NJ). Protease inhibitor cocktail 
was purchased from Sigma (St. Louis, MO). Enzyme Thrombin was obtained from GE 
Healthcare. Detergents N-Lauroyl sarcosinate (Sarkosyl) was purchased from Amresco (Solon, 
OH),   Dodecyl- β-D-maltoside (DDM) from Affymetrix and SDS from Fisher Scientific. 1,2-
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Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) lipid was purchased from Avanti Polar 
Lipids. Glass filter subtype B (GF/B) was obtained from Perkin Elmer. AKTA machines and 
chromatographic media were obtained from GE Healthcare. 3H-CP55,940 (specific activity: 88.3 
Ci/mmol), CP55,940, WIN55,212-2 and SR144,528 were obtained from RTI International 
(Research Triangle Park, NC). All other chemicals, unless otherwise mentioned, were obtained 
from Fisher Scientific (Pittsburgh, PA). 
 
3.2.2.2 Vector Construction of the pGEX 2T- GST-Thrombin-CB2-His 6 
The expression vector used in this study was based on the pGEX2T-M vector backbone that 
houses the GST tag sequence followed by a thrombin cleavage site. The parent vector was 
double digested by BamHI and EcoRI restriction enzymes for subsequent cloning. The construct 
used in the present study is shown in Figure 3.1B. The human cannabinoid receptor 2 (CNR2) 
gene was PCR amplified from the pcDNA3.1 3HA-CB2. The forward and reverse primers ( 
Forward 5’- AAG CTT GGA TCC ATG GAG GAA TGC TGG GTG ACA G -3’ Reverse  5’- 
AAG CTT GAA TTC CTA TTA ATG GTG ATG GTG ATG GTG ATC AGA GAG GTC TAG 
ATC TCT G-3’) included the restriction sites BamHI and EcoRI respectively for subsequent 
cloning. The reverse primer was designed to remove the last Cysteine residue from the CB2 gene 
and include the 6 Histidine (6His) tag sequence upstream of the stop codon and the restriction 
site.  The amplified CB2 sequence was double digested with the corresponding restriction 
enzymes and ligated into the doubly digested pGEX vector in frame downstream of the GST-
Thrombin sequence. The final construct contained the CB2 receptor with a N' terminal GST tag 
(separated by Thrombin cleavage site) and a C' terminal 6-Histidine tag. All construct sequences 
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were verified by automated DNA sequencing at the University of Pittsburgh Genomics core 
facility. 
 
 
3.2.2.3 Expression and Purification of the GST –Thrombin-CB2-6His  
 
Small scale expression of GST –Thrombin-CB2-6His  
Minicultures (5ml) were inoculated with single colonies from an LB-Ampicillin plate containing 
E. coli BL21 (or BL21 codon plus) freshly transformed with the expression construct pGEX2T-
GST-Thrombin-CB2-6His. Midicultures (50ml) were inoculated with the minicultures and 
grown overnight.  Maxicultures (1 L) were inoculated with the midicultures and grown until the 
culture reached an OD600 of 0.8. All bacterial cultures were inoculated in a 1:100 ratio (v/v) of 
the (saturated culture):(fresh media) in presence of Ampicillin (100 µg/ml) and grown in a 
shaker (at 250 rpm) at 370C. Expression of the recombinant CB2 protein was induced with 0.8 - 
1 mM isopropyl-β -D-thiogalactoside (IPTG), followed by continuous shaking overnight for 
about another 16 hrs at 27oC . Cells were harvested by centrifugation and the pellets were stored 
at -800C for further experiments. The protocol for expression and purification of the GST CB2 
was adapted from elsewhere (Park et al., 2012; Park et al., 2006).  
 
Preparation, enrichment and solubilization of Inclusion bodies 
Cell pellets were lysed by using a combination of mechanical and chemical lysis. Pellets were 
thawed on ice and lysed in buffer (20 mM Tris-HCl, 500 mM NaCl, 15% glycerol, pH 8.0) in a 
ratio of 50 ml lysis buffer per liter of cell pellet. Pellets were resuspended to homogeneity by 
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using a glass rod or by pipetting up and down gently. The slurry was tip sonicated for 5 mins 
under low or medium output control (3-8, Fischer Scientific Dismembrator Sonifier) with the 
sample on ice. 1mg Lysozyme (Fisher Scientific) was added to the sonicated mixture followed 
by 30 minutes incubation at room temperature with continual stirring. The slurry was centrifuged 
at 20, 000 rpm for 20 mins at 4°C. The pellet material was further resuspended in 20mM Tris-
HCl supplemented with 0.5% Triton X-100 followed by homogenization to remove any large 
particulate debris. The homogenized material was centrifuged again as the previous step and the 
supernatant discarded. This process was repeated upto three times to finally obtain the pellet 
material enriched with GST-CB2 inclusion bodies (IB). 
IB pellets were solubilized into the solution phase in a binding buffer (20 mM Tris-HCl, 
500 mM NaCl, 1% Sarkosyl, 10 mM immidazole, 10mM β-mercaptoethanol, pH 8.0). All the 
pellet materials were completely solubilized into the solution phase, gently and were then 
homogenized in ice to breakdown larger debris followed by vigorous stirring for 1 hour at room 
temperature. Addition of additional binding/ solubilization buffer can be done at this stage if the 
material is too viscous. Lower volumes of solubilization buffer will not be effective to extract all 
the IB material. On the contrary, large excess of the solubilization buffer will also lead to the 
dilution of the load material. The solubilized material contained all the IB and the insoluble cell 
debris and DNA. This was centrifuged at high speed 25000 rpm for 1 hr at 4°C. The supernatant 
collected from this step contained the solubilized IBs and other hydrophobic proteins. The 
supernatant material was collected and treated with DNA breaking enzymes (Pierce Universal 
Nuclease) in the ratio of 10U/ liter of culture. This incubation step was carried out at 4°C for half 
of an hour. Following, the load materials was filtered through a 0.45 micron filter. 
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Large scale preparative purification of GST-Thrombin-CB2-6His 
Purification of the solubilized IBs was carried out under denaturing conditions using a Ni2+ 
column (His Trap FF/ HisTrap FF crude GE Healthcare). The column was pre-equilibrated with 
the binding buffer and the flow through was collected while loading. The column was washed 
with 10 column volume of the binding buffer to completely remove any unbound material from 
the column. The column was then washed with binding buffer supplemented with 50mM 
Immidazole to washout the non-specifically bound proteins and enrich the column with the GST-
CB2. Next, 1000Units of the Thrombin Protease was injected to the column and incubated 
overnight at RT. The next morning the cleaved CB2 protein was eluted from the column in the 
cleavage buffer supplemented with 500mM Immidazole. A charged GST Trap was attached 
beneath the HisTrap column during the elution from the His trap. The GST Trap column to be 
used was washed with both 6M Guanidine Hydrochloride and 70% Ethanol to remove any 
nonspecifically bound proteins and/ hydrophobic contaminants followed by complete wash by 
1X Phosphate buffer saline (PBS). The attachment of the GST column with the HisTrap while 
elution was intended to to trap the uncleaved GST-CB2 and the free cleaved GST. 
Following elution from the IMAC column the eluted fractions were tested for the 
presence of the cleaved (and the percentage cleaved) CB2. The fraction with the cleaved CB2 
were pooled together and concentrated using an AMICON 30 kDa cut off concentrator 
(Millipore). The concentrated protein was further purified by Size Exclusion Chromatography 
(SEC) Superdex FPLC 26/60 (GE Healthcare). The column was pre-equilibrated with SEC 
buffer (20 mM HEPES, 0.5% SDS, 50 mM NaCl, pH 7.3). The fractions from the SEC was 
collected and were analysed by SDS PAGE and CBB staining if the samples get too dilute due to 
dilution from the SEC column the samples may be concentrated by TCA DOC precipitation to 
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get observable data from the SDS PAGE CBB staining. Similar to a SDS PAGE gel samples 
collected were also separated in a native PAGE gel. 
 
 
Thrombin Cleavage 
Thrombin cleavage reaction of the GST-Thrombin-CB2-His6 was carried out on the affinity 
column prior to specific elution. However several stages of optimization were implemented and 
excess of the protease was used for the cleavage reaction. Following the elution of the non-
specifically bound proteins, the buffer was exchanged in the column with the Thrombin protease 
Cleavage buffer (20mM Hepes, 250mM NaCl, 0.1% Dodecyl-beta-D-maltoside, pH-8.0). To 
ensure complete buffer exchange and removal of any remaining denaturants (Sarkosyl and β-
mercaptoethanol) from the column, it was washed with 20 CV of the cleavage buffer. Next, 1000 
Units of the restriction grade thrombin protease (GE Healthcare) was resuspended into 1 CV of 
the thrombin cleavage buffer and injected into the column. The column was closed at both ends 
and incubated overnight at RT. Following incubation with the protease, the column was 
reconnected to the AKTA system, line equilibrated and A280 absorbance was corrected to 
baseline level. After about 10CV washing with the cleavage buffer, the bound cleaved CB2 was 
eluted from the column with cleavage buffer supplemented with 500mM Immidazole. Fractions 
were individually analyzed on 10% SDS-PAGE. Densitometric analysis was done to determine 
the fraction of uncleaved and cleaved GST CB2 protein.  
Figure 3.2 shows a schematic flow diagram of the steps for the overall purification as designed 
and planned for the production of functional CB2 protein. 
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Figure 3.2. Overall steps involved in the extraction and purification of 
CB2 receptor inclusion bodies. 
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Overall steps involved in the extraction and purification of CB2 
receptor inclusion bodies.Extracted IB pellets from transformed bacteria 
would be first captured in the affinity column and processed for detergent 
exchange and protease cleavage. The cleaved protein of interest can be 
isolated by size exclusion chromatography. The process is depicted left-
right.  
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3.3 RESULTS AND DISCUSSION 
3.3.1 Expression and Purification of CB2 in fusion with TrpΔLE tag 
E. coli C43(DE3) cells were transformed with the fusion construct shown in Figure 3.1A. The 
recombinant protein was isolated from the bacteria as inclusion bodies and extracted therefrom 
using 10mM SDS.  Figure 3.3 shows a schematic flow diagram of purification and cleavage 
steps towards the generation of cleaved CB2 receptor in batch on a small scale experiment. In the 
first step of purification, a simple pH gradient IMAC chromatography was conducted (Appendix 
A Figure 4.10).  Trp∆LE-9His-Xa-CB2 was eluted from the IMAC column at pH 6.0, however it 
also contained other contaminating proteins at ~30 and 37 kDa as determined by SDS PAGE 
CBB staining (Figure 3.3A). To further purify and clean up the protein from IMAC, Trp∆LE 
protein was subjected to size exclusion chromatography using a Superdex column with little 
improvement of the protein purity (Figure 3.3B).   
The Trp∆LE-Xa-CB2 demonstrates a very high expression level of the fusion protein.  
The fusion protein can be purified in a relatively simple pH gradient chromatography and further 
purified and polished through the ion exchange and the SEC. However, we observed that the 
protein could not be purified as effectively in the immidazole gradient chromatography. The 
reason for this behavior by this construct is not well understood. Combined ion exchange and 
Size exclusion chromatography instead, allowed for the generation of a pure fusion protein 
which was used for the subsequent cleavage reactions. 
To determine the buffer conditions which may be more suitable for Factor Xa cleavage, 
the recombinant Trp∆LE-Xa-CB2 was exchanged using a 5ml ZebaSpin exchange system 
(Pierce) from 10mM SDS to different buffer environments. Cleavage efficiency was tested a 10X 
 75 
concentration of Factor Xa in 10mM SDS, 0.8% Triton X 100, 8mM Octyl Glucoside and 8mM 
DDM. As shown in Figure 3.3C, no appreciable loss of fusion protein was noticed in the 
exchanged detergent environments (Figure 3.3C).  
Further, the purified fusion protein was subjected to cleavage reactions in Triton X-100 in 
absence or presence of 10U of Factor Xa for 15, 45, 60, 90 and 120 minutes. Maximal cleavage 
of the fusion protein was observed between 60-90 minutes (Figure 3.3D). The cleavage mixture 
was incubated on a small scale with Nickel beads which leads to the removal of uncleaved 
proteins and isolation of the cleaved CB2 protein (Figure 3.3E). 
Developed purification process was implemented for the large scale expression and 
purification of the Trp∆LE-CB2 fusion proteins with the inclusion of an additional ion exchange 
chromatographic purification step (Figure 3.4). Initial pH gradient IMAC led to the isolation of 
the Trp∆LE –CB2 fusion protein with contaminating proteins (Figure 3.4A).  The Trp∆LE- CB2 
protein did not bind to charged ion exchange column and was collected in the flowthrough 
fraction. However this allowed us to capture and remove several contaminants on the column 
except only the presence of one at 30 kDa (Figure 3.4B). Following this step, the nearly pure 
Trp∆LE-CB2 fusion protein was subjected to size exclusion chromatography using a Superdex 
HiLoad column (Figure 3.4C). 
Factor Xa cleavage reaction of the Trp∆LE-9His-Xa-CB2 was challenging due to the 
hydrophobic nature of the protein and the susceptibility of the Factor Xa towards detergents. 
Factor Xa is derived from mammalian origin which works in a relatively aqueous environment.  
The structure of the protease enzyme and hence the activity is by obvious reasons, hampered in a 
hydrophobic milieu. On the other hand, the buffer containing high amounts of detergent is 
required to keep the fusion protein in solution. 
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To this end, it was necessary to carry out two imperative optimizations of the cleavage 
reaction. Firstly, the optimal amount of Factor Xa enzyme to be used for cleavage was required 
to be determined. Secondly, it was important to determine the optimal buffer conditions 
(detergent to be supplemented to carry out the cleavage reaction). All conditions were 
determined in batch to carry out the reactions with the control of time, temperature and buffer 
conditions and perform the cleavage reactions with the minimum amount of protein. In an effort 
to determine the ratio of μg of protein per units of Factor Xa, the cleavage reaction was first 
designed to try out different amount of factor Xa protease ranging from 0 to 1 enzyme units. 
Factor Xa treatment cleaves the 53 kDa fusion protein, Trp∆LE-9His-Xa-CB2 into two 
fragments Trp∆LE-9His (13kDa) and the CB2 receptor (40kDa). The Factor Xa enzyme has a 
molecular weight of 43 kDa. According to the manufacturer’s protocol, 1U of enzyme per 50µg 
of the protein is recommended as optimal. Using 0U, 0.02U, 0.5U and 1.0U concentrations of the 
protease, successful cleavage and the appearance of cleaved bands were noticed only at 1U 
concentration (Appendix A Figure 4.11). Increasing the amount of enzyme may compensate for 
its decreased activity in the hydrophobic buffer and also account for any steric occlusion that 
may result from the buried nature of the cleavage site in a relatively less denaturing environment.  
This cleavage efficiency and the high amounts of both the detergent and Factor Xa made 
it more difficult to carry on with this fusion construct. The principal reason of failure and 
complications can be attributed to the high degree of hydrophobicity that is conferred from the 
Trp∆LE fusion partner. We faced a catch 22 situation where the solubilization of the fusion 
construct required high amounts of detergents which is not favored by the protease and its 
activity is lost or reduced dramatically. The Trp∆LE system was hence not pursued further 
towards the cleavage, detergent exchange and refolding. 
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Figure 3.3.  Expression, purification, detergent exchange and cleavage optimization 
of the Trp∆LE -CB2 fusion protein in batch 
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Expression, purification, detergent exchange and cleavage optimization of the Trp∆LE -
CB2 fusion protein in batch. Trp∆LE leader fragment was used to direct the overexpression of 
CB2 into inclusion bodies. (A) CB2 receptor inclusion bodies were purified by pH gradient  
affinity chromatography (Ni2+) column. The protein of interest (Trp∆LE -9His-CB2 : 53KDa) 
was polished by size exclusion chromatography (SEC) (B) following detergent exchange (C) 
with Triton X 100 (TX), Octyl Glucoside (OG), Dodecyl maltopyranoside (DDM) or no 
exchange (NE) to determine the amount of protein retained in different detergent solutions. (D) 
The fusion protein in TX was treated with Factor Xa protease for different incubation times and 
(E) cleaved product separated by subtractive IMAC using Ni2+ sepharose beads.  
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Figure 3.4. Scaled–up purification steps for the SDS solubilized Trp∆LE -CB2 
fusion construct 
The fusion protein solubilized in SDS was purified stepwise by (A) pH gradient IMAC 
chromatography.  Proteins were loaded to HisTrap at pH 8.0 and the POI eluted at pH 
6.0. (B) Subtractive ion exchange chromatography using an SP-FF column. POI 
collected in the flowthrough. (C) Preparative Size Exclusion chromatography. Protein 
obtained post size column was ≥ 80-90% pure.  
 80 
3.3.2 Expression and purification of CB2 in fusion with GST tag 
E. coli BL21 cells were transformed with the fusion construct shown in Figure 3.1B. The 
recombinant protein was isolated from the bacteria as inclusion bodies and extracted therefrom 
under denaturing conditions in presence of 1% Sarkosyl.  Figure 3.5 shows results from the steps 
involved in a small scale (in batch) purification, detergent exchange and cleavage procedures of 
CB2 receptor from the inclusion bodies enriched with the fusion GST-Thrombin-CB2- 6His 
protein (66 kDa). In the first step of purification as shown in figure 3.5A, the solubilized 
enriched inclusion bodies of CB2 fusion protein was purified by IMAC using a Ni2+ column. 
Elution with 300 mM Imidazole yielded the protein to a good degree of purity. As shown in 
figure 3.5B, detergent was exchanged from 1% Sarkosyl to 0.1% DDM by using the ZebaSpin 
buffer exchange column and no significant loss of the GST CB2 was observed. Partial cleavage 
of ≥ 60% was achieved using the Thrombin protease under these conditions (Figure 3.5C).  
Separation of the cleaved and uncleaved protein was attempted by incubating the cleavage 
reaction mixture with GST beads. The reaction mixture was centrifuged and the supernatant 
subjected to SDS-PAGE and Western Blotting. CBB staining revealed the presence of 
successfully cleaved CB2 in the supernatant (Appendix A Figure 4.12;  Panel A). Immunoblot 
analysis with anti-His (Figure 3.5D), anti-CB2 and anti-GST (Appendix A Figure 4.12;  Panel B) 
antibodies confirmed the presence of successfully cleaved CB2 in the supernatant. Thus, GST 
beads were effective in the removal of the uncleaved GST-CB2 and the free released GST 
protein from the cleaved population in the reaction mixture. 
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Figure 3.5. Expression, purification, detergent exchange and cleavage optimization of the GST-
CB2 fusion protein in batch 
 (A) CB2 Receptor Inclusion (GST-CB2) bodies were extracted by detergent Lauryl Sarkosyl 
and were purified by affinity chromatography (Ni2+) column. (B) The purified protein of interest 
(GST-CB2-His6 : 66KDa) was exchanged using a Zeba Spin to remove  the detergent Lauryl 
Sarkosyl with 0.1% DDM. (C) Thrombin cleavage was carried out for 16 hour at RT and 
incomplete cleavage was noticed. This yielded a mixture of parent protein, cleaved product and 
the released GST tag.  (D) This mixture was incubated with GST-Sepharose beads for 1 hour at 
room temperature under mild agitation to separate the cleaved and uncleaved protein .Western 
Blot (Anti-His) analysis of the supernatant fraction.  
 
 
 
Figure 3.6 shows the relative size and disposition of the tags before and after thrombin 
cleavage. Cleavage with the Thrombin protease results in the generation of two fragments (~ 40 
and 26 kDa) corresponding to the molecular weight of the free CB2 and the free GST tag 
respectively (Figure 3.6A). The presence of cleaved and uncleaved protein in the cleavage 
reaction was verified by immunoblotting with anti-His, anti-CB2 and anti-GST antibodies. As 
shown in figure 3.6B, probing with anti-His and anti-CB2 revealed bands at 40 and 66 kDa 
corresponding to the cleaved and the uncleaved fused CB2 receptors respectively. Anti-GST 
western Blot showed bands for the uncleaved parent protein at 66 kDa (Figure 3.6B).  
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Figure 3.6. Thrombin cleavage of the GST-CB2 fusion protein 
 
 (A) Cartoon showing the overall disposition of the fusion protein 
with the location of the  GST fusion partner, thrombin cleavage site 
and the CB2 receptor in the uncleaved fusion construct  (66KDa). 
Cleavage with thrombin yields two fragments – GST ~26kDa and 
the His tagged CB2 receptor ~40kDa. (B) Products yielded after the 
cleavage were verified by Western blotting and was probed against 
Anti-Histidine, Anti-CB2 and Anti-GST antibodies. 
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For a large scale purification from 8 liters of bacterial culture, the steps in purification was 
modified to a little extent. A flow diagram of the steps involved and the results are depicted in 
figure 3.7. A complete one step IMAC procedure was designed and implemented for binding the 
protein to the column, followed by “on-column” buffer exchange and thrombin cleavage and 
elution of the bound GST-CB2 fusion protein. Figure 3.7 shows the chromatogram for the 
combined process. Solubilized GST-CB2 in 1% Sarkosyl was loaded to a His Trap column 
charged with Ni2+ (Figure 3.7, step A) and the column was washed to remove unbound and non-
specifically bound materials (Figure 3.7, step B). Buffer was exchanged on-column for 20CV 
(Figure 3.7, step C) prior to the cleavage step. The large amount of the buffer passed through the 
affinity column binding the protein ensured the complete “on-column” buffer exchange. This 
allowed for the complete replacement of 1% Sarkosyl with 0.1% Dodecyl maltoside (DDM). 
Next, 1000 U of thrombin protease was injected into the column and incubated overnight (Figure 
3.7, step D). The cleaved protein was eluted from the column by washing the column with the 
thrombin cleavage buffer supplemented with 500mM imidazole (Figure 3.7, step E). 
Our small scale batch experiments have indicated that the GST can bind to the 
glutathione ligand (GST Trap Sepharose) while in the thrombin cleavage buffer and effectively 
allow the separation of the uncleaved GST-CB2 and the free cleaved GST from the cleavage 
mixture. Using this knowledge a clean and charged GST Trap (GE Healthcare) column was used 
in the step of the IMAC procedure. The column was attached beneath the HisTrap as the bound 
CB2 (and also the uncleaved GST CB2 and the associated GST) was eluted from the HisTrap in 
the Thrombin cleavage buffer.  
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Figure 3.7.  Step-wise purification, detergent exchange and on-column thrombin 
cleavage of GST-CB2 fusion protein 
Multistep purification and on-column cleavage process was designed for the expression 
purification and cleavage of the CB2 receptor. (A) The GST CB2 extracted in 1% Sarkosyl was 
loaded to the HisTrap. (B) Unbound and non-specifically bound proteins were eluted by washing 
the column with loading buffer supplemented with 50mM Immidazole. (C) Following this, 
HisTrap column was washed with 20 column volumes (CV) of the thrombin cleavage buffer 
(DDM). (D) Thrombin 1000U was injected to the column dissolved in cleavage buffer (1CV) 
and was incubated for 16 hrs at RT. (E) Column was connected back to the pre-equilibrated 
system and the unbound non-specific proteins were eluted followed by the elution of cleaved 
CB2 receptor in thrombin cleavage buffer supplemented with 500mM Immidazole. 
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The eluted fraction from the IMAC procedure was was cleaned by Zip Tip  and next subjected to 
MALDI TOF mass spectrometry. MALDI TOF analysis with the eluted cleavage mixture 
(obtained post affinity chromatography) (Figure 3.8) showed the presence of uncleaved parent 
GST-CB2 (~ 62.3 kDa), cleaved CB2 (~38.1 kDa) and free GST (~26kDa). The high amount of 
noise in the spectrum was contributed by the presence of detergents in the cleavage buffer in the 
eluted sample. However, MALDI-TOF analysis of the eluted fraction revealed presence of all the 
three entities in the mixture population. Thus, we found moderate to no improvements in the 
removal of uncleaved CB2 and the free GST fragment by using the GSTTrap in line with the His 
Trap column while elution. This inefficiency can be attributed to the fact that the interaction 
between the glutathione ligand and GST is relatively slower and the GST Trap is unable to bind 
and remove the contaminants at a flow rate of 3 ml/min in which the protein was eluted. 
Next, size exclusion chromatography was conducted to further separate out and purify the 
cleaved CB2 from the cleavage mixture. SEC chromatogram obtained with the cleavage mixture 
resulted in separation by overlapping peaks when separated through 30ml Superdex column. 
However the cleaved CB2 (MW~35kDa) was isolated clearly in the fraction 5 of the 
chromatogram (Figure 3.9A). The presence of the cleaved receptor in the fraction 5 was verified 
by SDS-PAGE and CBB staining (Figure 3.9B). To determine the presence of higher order 
structures it was important to separate the proteins by native PAGE. This allowed for the 
visualization of the higher order structures and their relative amounts in the gel. The protein 
obtained from the SEC showed a single band in a native PAGE gel confirming the absence of 
any higher order structure formation (Figure 3.9C). This sample was then exchanged to the 
mildly denaturing buffer which serves as an ideal starting point for refolding procedures. 
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Figure 3.8. MALDI-TOF mass spectrometry analysis of the cleavage mixture.   
C
le
av
ed
 C
B
2 
(3
8.
1 
K
D
a)
G
ST
(2
6K
da
) 
C
on
ta
m
in
an
tU
n-
C
le
av
ed
 G
ST
-C
B
2 
(6
2.
3 
K
D
a)
 
% Intensity
 88 
 
Protein eluted from the IMAC column following cleavage was composed of the uncleaved parent 
protein, cleaved protein of interest and the free GST. This ternary mixture is in the buffer 
containing detergent Dodecyl-beta D maltoside (0.5%). The detergent removal was attempted by 
using a 10μl Zip Tip (Millipore). Zip tip was pre-equilibrated with the mobile phase for the mass 
spectrometer (70% Acetonitrile, 30% Water). Clarified protein were spotted on a MALDI plate 
and the spectra was acquired in a  Voyager MALDI-TOF in linear positive mode. Results show 
the presence of the three components and a high background noise due to the presence of 
detergent DDM. 
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Figure 3.9. Size Exclusion Chromatography (SEC) and Detergent exchange of 
protein post cleavage. 
Eluent protein from the IMAC column comprised of a mixed population of the parent 
CB2, cleaved CB2 and the free GST. These were separated by SEC using a Superdex 
FPLC column. (A) Chromatographic profile showing the presence of several higher 
order structures along with the protein of interest (POI). (B) POI was eluted under the 
“peak 5” as seen by the SDS PAGE CBB staining. SEC additionally helps for buffer 
exchange from 0.1% DDM to 0.5% SDS. (C) Proteins were separated by a Native 
PAGE and were stained by the CBB stain. No higher order structures dimers/ 
monomers were noticed.  
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3.3.3 General Discussions 
The GST expression system and the thrombin protease offers several advantages compared to the 
Trp∆LE expression system. Firstly the GST fusion tag serves both as an expression enhancer and 
a tag which can be used for the purification even in the presence of detergents. However 
maintaining a non- denaturing condition is very important while carrying out GST tagged protein 
purification.  
To enhance the expression and yield of the protein of interest, it is imperative to ensure 
that the bacterial cells can transcribe the exogenous gene and thus express the recombinant 
protein to the maximum efficiency.  Codon optimization of the sequence of the structure gene is 
a very important parameter to aid in the efficient expression of the “payload” protein. The 
tRNA’s which suffer from the rare codon mismatch problem between the eukaryotic and the 
prokaryotic systems include the amino acids Arg (R), Isoleucine (I), Proline (P) and Leucine (L). 
To account for this discrepancy, either the construct sequence can be codon-optimized or a 
bacterial cell line capable of superior handling of rare codons can be used for the expression. 
Several bacterial expression strains have been designed and modified to include the tRNA’s 
coding for the rare codons present in eukaryotic cDNA.  Online predictive tools like 
https://www.idtdna.com/CodonOpt?c=US help determine the amount and the percentage of the 
rare codons and also generate codon optimized sequences from a starting parent gene. 
Fusion of GST tag to the CB2 gene, does confirm some degree of toxicity to the cells. 
The combination of BL21 cells transformed with pGEX expression vector leads to transcription 
of the exogenous gene under the control of the tac promoter. On the other hand, any DE3 strain 
of cell would initiate transcription under the influence of the strong T7 promoter. Expression of 
the fusion construct was hence preferred in a non-DE3 bacterial strain like BL21 cells for 
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controlled expression of the POI to reduce levels of toxicity. With a similar intention to control 
the disadvantage of toxicity in cells, we induced the cells at a relatively much higher OD600. This 
would allow the cells to increase in number (biomass) before induction. Post-induction the cells 
would not grow as healthily as before, due to the toxicity of the protein expressed. The larger 
biomass per unit of culture volume could compensate for the lesser amounts of protein produced 
in the individual cell level. Procedural modifications that support increased protein production by 
modifying the DNA sequence or decreasing the toxicity of the protein produced in the cell can be 
implemented together and would synergistically work to improve the expression level of the 
protein production. 
The cell pellet obtained must be processed in a manner to partially purify the protein of 
interest, or enrich the inclusion bodies. This essentially entails separation of the soluble proteins 
from the membrane bound proteins (by solubilizing them with Triton X 100).  Several 
hydrophobic proteins tend to associate with the IBs which can be separated by washing them 
with non-specific detergents. Thus, it is important to resuspend the pelleted material completely 
in the washing steps.  
The protease cleavage is a key step within the purification and absolutely required in a 
case when the fusion partner protein is relatively large or its removal is important for the proper 
folding of the receptor protein. This is because the presence of the fusion partner can affect both 
the physical and chemical properties of the fusion construct e.g. solubility, overall shape, charge 
state, molecular weight etc. However it is also important to consider what this may mean for the 
protein of interest before and after the cleavage.  For example for a relatively hydrophobic fusion 
construct cleavage and release of the fusion partner “tag” from the “protein of interest” may 
result in an enhancement of the solubility of the “protein of interest” and vice versa. A 
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comprehensive review of different proteases and their removal strategies have been listed in the 
Section 1.1.4. During the process development steps, it is to be noted that we found a steady and 
relatively high speed of protease injection for “on-column” cleavage is required to spread the 
protease to all corners of the column homogenously. 
Another key factor to be considered while purification and refolding is formation of 
higher order structures of the purified receptor. These may include dimers, trimers and other 
oligomers. The propensity of formation of higher order structures is driven by concentration of 
the monomer and the relative proportion of the monomers:oligomers. To separate the uncleaved 
proteins and the free GST from the CB2 and also exclude any higher order formation it is 
extremely important to separate the contaminants (and other higher order structures) by Size 
Exclusion Chromatography (SEC). Secondly, the Size column can be used as an effective tool 
for buffer exchange to introduce a relatively more stringent denaturing condition in preparation 
for the subsequent refolding steps. 
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3.4 CONCLUSION 
Overall inclusion body directed expression of the CB2 receptor can lead to overexpression and 
purification of the CB2 to homogeneity. In our first approach using the Trp∆LE-Xa-CB2 we 
were able to express in large amounts and purify the Trp∆LE-CB2 protein to ≥90% purity. 
However the entire fusion construct was rendered extremely hydrophobic due to the presence of 
the Trp∆LE fusion partner and purification was carried out in harsh detergent (10mM SDS). 
Inspite of the fusion protein being stable in the high amounts of denaturing detergents, we were 
unable to carry out protease cleavage in this high detergent concentration. Lowering the 
detergent would lead to partial or complete loss of the fusion protein from solution by 
precipitation. Due to these reasons we switched to the GST tagged CB2 receptor fusion protein 
IB expression. The GST tag confers greater solubility of the fusion protein, provides additional 
advantage of protection from proteolytic cleavage and can also be used for affinity purification 
or removal.  Using the GST tagged CB2 we developed a complete on column protein 
purification, detergent exchange and cleavage procedure. The cleaved CB2 receptor obtained 
from this procedure was exchanged to 0.5% SDS which was subjected to refolding procedures 
which will be discussed in the next section. 
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4.0  REFOLDING STRATEGIES AND BIOPHYSICAL ANALYSES 
4.1 INTRODUCTION 
 
4.1.1 Driving forces in protein folding 
The first high resolution or atomic level structure of proteins was observed during the 1960s 
which heralded a new understanding of regularity and orderly arrangement in structures. This led 
to the speculation about how the primary structure of a protein dictates its folding arrangement 
and hence it’s functional native structure. That the amino acid sequence is necessary and 
sufficient for complete folding of the protein was shown by Christian Anfinsen and co-workers 
(Anfinsen, 1973). It was believed since long that folding of protein involves an interplay of 
several interactions that can be ionic or hydrophobic in nature. However, around the 1980s it was 
proposed theoretically that folding is brought about primarily by hydrophobic interactions 
(Figure 4.1). Electrostatic interactions can be ruled out as the proteins have much lesser charged 
residues on the surface and that these are concentrated near surface patches which have high 
dielectric constant. Hydrogen bonding plays an important role in the process of protein folding. 
The hydrogen bonding interactions among the backbone amide and the carboxyl group in a 
protein is a key component of all secondary structures (α-helical and β-pleated sheets).  
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However, the backbone Cα-Nα tracing is similar for all proteins. It plays an important role 
in protein folding but is not a decisive factor since all proteins have similar hydrogen bonding 
interactions. It is therefore clear that side chains determine the route of folding and that it is 
mediated by hydrophobic interactions. Several reasons can be suggested to support this statement 
: (a) A major structural element in proteins is the presence of the hydrophobic core in which all 
hydrophobic amino acids are sequestered; (b) Computational studies show energy difference and 
stabilization by 1-2 Kcal/mol for transferring a hydrophobic side chain from an aqueous to an 
“oil-like” media (Wolfenden, 2007); (c) A non-polar solvent can readily denature a protein; and 
(d) Jumbled sequences of proteins which retain their polar and non-polar sequences (and no other 
significant stabilizing force) can fold to their expected native structures in the renaturing 
environment (Bradley et al., 2007; Cordes et al., 1996; Hecht et al., 2004). Alpha-helical and 
beta-pleated sheets provide the opportunity to pack up the long polypeptide chain into an orderly 
arrangement which is reminiscent of an airport security-check waiting line. Studies on “lattice 
models” and “tube models” of proteins have shown that the overall protein structure is stabilized 
by the chain compactness which is indirectly controlled by the hydrophobic force to collapse. 
Hence it is important to understand that protein sequences containing regular repeats or patches 
of hydrophobic sequences have the ability to fold into native functional structure as long as the 
correct milieu is available. 
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Hydrophobic interaction is the pre-dominant interaction 
Protein Domains 
Unfolded protein Folded  protein
 
Figure 4.1. Interactions in protein folding.  
 
Individual domains in the protein is brought together from the 
denatured protein predominantly by hydrophobic interactions.  
Other interactions like ionic –interactions, hydrogen bonding and 
Van der waals interactions  also contribute to receptor folding. 
 
 
 
 
4.1.2 Membrane protein refolding 
Membrane proteins are special cases of proteins in which a reversed arrangement of the 
hydrophobic and the polar groups have been evolutionarily favored due to their location in the 
membrane and the presence of the lipid belt region. Membrane protein refolding is convoluted 
both by their complicated nature and the lack of reproduction of “native lipidic” condition in 
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which the proteins can refold to functionality. It is to be noted that the process of folding and 
insertion of the membrane proteins α-helical and β-barrel is not well understood. The precise 
control of this process is facilitated at various steps including the endoplasmic reticulum (ER) 
and during membrane insertion. Thus, many studies were directed to the understanding of 
membrane protein trafficking (Tan et al., 2004). The refolding of Alpha helical proteins will be 
under consideration due to the alpha helical nature of all GPCRs. Computational biophysical 
studies have started to provide the theoretical basis (Booth and Curran, 1999) of the membrane 
protein folding process. The process of studying purified membrane protein refolding is 
cumbersome due to the low solubility of the membrane protein and lesser shelf time of the 
starting materials for refolding trial experiments. This is why majority of biophysical studies of 
membrane protein refolding has been done on the bacteriorhodopsin which is much more stable 
in a detergent environment than a typical membrane protein and serves as a model system for 
understanding the principles of membrane protein. A general pathway of two-stage refolding has 
been suggested for α-helical IMP (von Heijne, 2011). During the first step the transmembrane 
helices take shape and the extra and the intracellular connectors also start taking up their shape 
and form. This process is facilitated by the stability of the hydrogen bonding between the 
backbone amide and the carbonyl group which more stable in the low dielectric environment.  
In the second step of the refolding process it is assumed that individual helices come 
together and organize themselves into the most energetically favorable structure. During this step 
there is a competition between the propensity of the protein to refold or aggregate. Refolding will 
occur when the intra-molecular interactions will be favored over the inter-molecular interaction. 
It is widely accepted and noticed that increasing the concentration of the unfolded solubilized 
membrane protein leads to their aggregation and precipitation from the solution phase.  In a more 
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refined theoretical model a third step of ligand binding, folding of the loops and the final 
formation of the quaternary structure has been proposed (Weik et al., 1998). The balance 
between aggregation and refolding also largely depends on the refolding environment and an 
intricate balance must be reached between the “too harsh” and “too mild” environments. To 
determine the correct condition different parameters like pH, salt, protein concentration can be 
changed. However the composition and amount of the detergent, detergent-lipid or lipid in the 
refolding environment always poses as the most crucial factor. 
 
4.1.3 Current refolding strategies of GPCRs from inclusion bodies  
The process of refolding is arrived at after the high level expression, solubilization and 
purification of the GPCR IBs. Refolding strategies may be classified into two pathways 
depending on the nature of the stabilization environment; the traditional detergent-lipid pathway 
and the amphipol or proteic pathway (Figure 4.2). The approach to each of these pathways has 
been described in the next page. 
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Figure 4.2.  Schematic diagram representing the pathway of refolding the 
CB2 by “lipidic” and “proteic” pathways. 
Both methods require the cleaved CB2 receptor in the denatured condition 
(0.5% SDS) (A) Lipidic refolding pathway requires the generation of the CB2, 
SDS and DMPC ternary complex and the controlled removal of the SDS by 
dialysis to provide lipid enrichment. (B) Amphipol mediated refolding was 
carried out by the rapid removal of the SDS by KCl precipitation. 
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It is to be noted that almost all membrane protein including GPCRs retain significant amount of 
alpha helical (or secondary structure) content in SDS (Miller et al., 2009; Muller et al., 2008). 
About 40% alpha helicity was retained in the μ-opoid receptor at the pH of 7-8 in a 0.1% SDS 
solution (Muller et al., 2008) which is slightly less than the total alpha helical content in the fully 
functional receptor. All these studies taken together suggest that the SDS-solubilized receptor is 
“partially prefolded” and this “not-harsh-enough” does not completely unfold the protein of 
interest. Initiation of folding from the SDS-solubilized receptor has been undertaken by the two 
popular alternative approaches using “lipidic/DMPC” and “proteic/A8-35” stabilization matrices. 
 
4.1.3.1 Refolding the GPCRs  in lipidic matrix 
Refolding the denatured SDS-solubilized GPCR in a membrane mimetic base seems to be the 
most rational strategy. Although the native eukaryotic membrane has a precise composition of 
various lipids, a similar environment can be generated by amphipathic molecules including but 
not limited to detergents, lipids, detergent-lipid mixtures, bicelles and lipid vesicles. The 
leukotriene receptor 1(BLT 1) was refolded in 30% Lauryldimethylamine-N-oxide (LDAO) 
(Baneres et al., 2003) and the BLT2 was refolded to its functional state in n-dodecyl 
phosphocholine (DPC): hexadecyl-β-D-maltoside (HDM) mixtures (Arcemisbehere et al., 2010). 
It was also found that the addition of asolectin improved the percentage of functional recovery in 
both the cases. In a more recent study the human parathyroid hormone receptor 1 and the mouse 
CB1 were refolded in the non-ionic detergents DDM and Cymal6.  Similarly the olfactory 
receptor OR5 was solubilized in Sarkosyl, refolded within the non-denaturing detergent digitonin 
and exchanged to lipids like the POPC / POPG mixtures. 
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4.1.3.2 Refolding GPCRs in Amphipol 
Amphipols are synthetic alternatives to mild detergents and have successfully shown stabilizing 
effects for the refolding of GPCRs in denaturing environment. Amphipols have been defined as 
“amphipathic polymers”. It was noticed that integral membrane proteins are generally much 
more stable in amphipol environment and such stabilization assists in folding the GPCRs to the 
native state. The prototypic Amphipol A8-35 have demonstrated stabilization role for several 
GPCRs. Conditions for refolding in Amphipol that were initially developed for the 
bacteriohodopsin were applied to six different GPCRs like Leukotriene B4 receptors (BLT1, 
BLT2),  serotonin receptor 5HT4A, CB1, ghrelin receptor (GHSR1a) and the vasopressin V2 
receptors (Baneres et al., 2011). Amphipols provide a very dependable environment in which 
there is a high probability of newer GPCRs to be refolded.  Further, GPCRs which showed 
functional reconstitution within the lipids showed much better functional activity within the 
amphipols. However the refolding of denatured GPCRs in a new environment is case specific 
(Figure 4.2 B).  
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Table 4.1. Comparison of GPCR folding yields obtained in different surfactants 
Adapted from (Baneres et al., 2011). 
Receptor Surfactants used 
Average maximum 
folding yield (%) 
BLT1 
Detergent-lipid mixed micelles (LDAO-asolectin) 30 
A8-35 50 
A8-35-asolectin 65 
BLT2 
Detergent-lipid mixed micelles (DPC-HDM-
asolectin) 
4 
A8-35 50 
A8-35-asolectin 70 
CB1 
Detergent-lipid mixed micelles(Fos-choline-16-
asolectin) 
0 
A8-35 30 
A8-35-asolectin 40 
Detergent mixed micelles (DDM-Cymal 6) 30 
5-HT4A 
DMPC-CHAPS bicelles 25 
A8-35 30 
A8-35-asolectin 60 
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4.2 MATERIAL AND METHODS 
4.2.1 Refolding the CB2 in lipidic stocks 
The procedure involves denaturing the CB2 with SDS and then controlled removal of SDS 
after introducing the refolding lipid. The lipidic matrix was prepared by dissolving dessicated 
powder of 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) (Affymetrix) in the SEC 
buffer (20mM Hepes, 250mM NaCl, 0.5% SDS, pH-8.0) to get a final phospholipic 
concentration of 10mg/ml. The receptor protein obtained from the SEC was mixed with the 
phospholipid solution gently. The Protein:SDS:DMPC complex was mixed together and 
incubated for an hour to allow for complete equilibration of the reaction mixture. Following the 
incubation, the SDS was removed in a controlled fashion. Two step dialysis procedures were 
performed – in the first step, the reaction mixture was dialyzed overnight at room temperature 
against refolding buffer (20mM HEPES, pH-7.3). Dialysis was carried out with the protein in a 
Slide Lyzer cassette against about > 200 folds of the refolding buffer. Next, the buffer was 
exchanged to a fresh refolding buffer supplemented with 20mM KCl and dialysed for an 
additional 6 hrs at RT. The SDS in the ternary mixture was precipitated by the co-incubation 
with the KCl. The contents of the dialysis bag were transferred into prechilled polycarbonate 
tube to facilitate further precipitation of the SDS. The precipitated SDS was removed by high 
speed centrifugation (50,000xg, 30mins, 4°C). The protein concentration was determined by 
BCA assay. A quick  snapshot of the procedural steps to refolding is illustrated in Figure 4.3. 
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Figure 4.3.  Overall methodology involved towards purification and refolding of the 
denatured- fused  CB2 from  inclusion bodies. 
 
 
 
Harsh detergent  SDS / Lauryl Sarkosyl 
(complete denaturation)
Affinity chromatography
Detergent Exchange 1
Protease cleavage – release of cleaved CB2
Refolding in Lipidic 
environment 
Amphipol  mediated 
refolding 
A8-35
DMPC
Denatured  monodisperse protein
Detergent Exchange 2
GST/TrpLE
 105 
4.2.2 Amphipol assisted CB2 refolding 
The purified protein (in 0.5% SDS) was mixed with Amphipol A8-35 (Affymetrix) and 
Asolectin (a combination of Phosphatidylcholine, Phosphatidylethanolamine, 
Phosphatidylinositol, Phosphatidylserine) (Sigma Aldrich) in the ratio of 1:1:5 (by weight). The 
quaternary complex was incubated for 1 hour. Following this, the SDS removal was initiated by 
the addition of 150mM excess KCl (pH 8.0). The KCl solution was added rapidly in one shot to 
the reaction mixture to obtain a final concentration of 200mM. The solution system was mixed 
well gently and incubated at RT for 1 hour. The precipitated SDS was removed by high speed 
spin (50, 000 rpm, 30 mins 4oC). The supernatant was dialyzed overnight against 20mM 
Potassium Phosphate, 200mM KCl pH 8.0, followed by a fresh change of the dialysis buffer and 
an additional 6 hour dialysis. The contents of the bag were transferred into a prechilled 
polycarbonate tube and incubated on ice for ~15 mins to facilitate further precipitation of any 
remaining SDS. High speed spin (50,000xg, 30mins, 4°C) and incubation on ice was repeated 
twice for the complete removal of the SDS. Supernatant material was collected, protein 
concentration analyzed by BCA assay and saved at 4°C for characterization. Characterization 
was done by ligand binding capability of the reconstituted receptor protein. 
4.2.3 Radioligand Binding assays 
Radioligand binding was performed to determine the percentage of specific binding of a ligand 
to the purified refolded receptor. Saturating amounts of ligands were used in the Saturation 
Binding Assay while the Competitive ligand displacement assay measured the capability of one 
ligand to displace the other for binding to the receptor.  
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Receptor Saturation Binding Assay  
In a “U –bottom” 96 well plate, buffer base and assay components were added in the order as 
mentioned below. Incubation buffer (InB) (50mM Tris HCl, 2.5mM EGTA, 5mM MgCl2, 
1mg/ml BSA, pH 7.4) was added in a volume of 90ul per well for a 200ul assay mixture (80ul in 
wells for measuring the non-specific binding). The 3H-CP 55,940 was diluted through a range of 
concentrations by using the Compound Dilution Buffer (CDB)(2mg/ml BSA, 2.5ml TME, 2.5ml 
of DMSO, 4ml of 2.5% Methyl Cellulose and 3.5 ml water/ 25ml of the CDB buffer). A 10X 
TME buffer stock solution was prepared (by adding 27.5 grams of Tris Base, 43g of Tris HCl, 
9.51g EGTA, 10.165 g MgCl2, pH 7.4). The radioligand 3H-CP 55,940 (Research Triangle 
Institute, NC) was diluted in the CDB upto a final concentration of 4054.3nM. Dilution was 
performed by using the equation 
Concentration of Radioligand (M) = radioactivity concentration (mCi/ml)/ [specific 
activity (Ci/mmol)*1000 (mCi/ml)] 
Saturation Binding assay was performed in triplicate to determine the Total and the Non 
Specific binding respectively. The Specific binding is the difference between the Total and 
Nonspecific binding. In triplicate wells designated for non-specific binding measurement, 10µl 
of 100µM cold ligand (cold CP 55,940) was added to a final concentration of 5µM. 10 µl of the 
3H-CP 55,940 was added to eight wells over a concentration range of 50 – 400 pM.   Protein 
samples (proteoliposomes DMPC/A8-35) were added upto a final concentration of 300 pg/well 
diluted in 100 µl. Components in the wells were mixed gently and incubated at 30°C for 1 hr 
with gentle shaking. Following incubation the assay mixture was harvested by a Filter Mate 
Harvester (Perkin Elmer) into a 96 well GF/B plate (pore size 1.0 micron). The filter plate was 
dried overnight. Next, 30µl of Micro Scint liquid (Perkin Elmer) was added to each well of the 
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GF/B plate and incubated in dark for 15 minutes. The counts per minute from the wells were 
read in a Top Counter reader.  
 
Competitive Binding Assay  
Competitive Binding Assay was performed in the similar 96 well plate format. Several buffers 
used in the Saturation binding namely the Incubation Buffer, Compound Dilution Buffer are 
identical in the assay. The compound powders were dissolved in 100% DMSO and were diluted 
to concentrations ranging from 0.01 nM to 1.0 mM. Selection of eight points for the assay and 
ligand dilution was determined such as the Ki value is the closest to the midpoint of the dilution 
range. The exact concentrations of the proteoliposomes do not significantly matter and assays 
were conducted with 300- 2000 pg/well. Results and the effects of changing the proteoliposomes 
amounts per well will be discussed in the following section.  Assay components were added in 
the 96 well plate in the order of incubation buffer (30ul), cold competing compound (20ul), 50 ul 
of the ligand 4nM final concentration. Proteoliposomes were added in the last step. Liposomes or 
CB2-APol mixtures were diluted in the refolding buffer and the KP buffer respectively. During 
the process of preparation of the liposomes and final dilution, care was taken to make a 
homogeneous mixture and the same amount of proteoliposomes was added to all the wells. The 
final assay mixture (200ul) was mixed well and the plate was incubated at 30°C for 1 hr with 
gentle agitation in an orbital rotor. Following the incubation step the plate was harvested, dried 
and read from the GF/B as mentioned for the Saturation Binding assay in the previous section.  
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4.3 RESULTS AND DISCUSSIONS 
4.3.1 Purification and conditioning the CB2 for refolding processes 
The correct processing of the cleavage and detergent exchange steps are necessary for the 
successful refolding to take place. If the starting material of the refolding experiment is not in the 
correct disposition then the refolding process can fail. The correct conditions include but are not 
limited to several conditions as discussed below. Homogeniety of the protein sample is perhaps 
one of the most important factors to get the protein to the correct refolded state. The Size 
exclusion chromatography (SEC) steps works in the same lines to further polish the eluted 
protein.  SEC chromatogram obtained with the cleavage mixture resulted in separation by 
overlapping peaks (Figure 3.9A). 
4.3.2 DMPC assisted refolding 
Proteoliposomes were prepared by the process as discussed above and is shown by the schematic 
Figure 4.2A. The DMPC lipids provide and act as a surrogate environment for the refolding of 
the protein (Figure 4.4A). Since the refolding process is a complicated interplay between several 
conditions, it is difficult to critically evaluate method design and end-point correlation. To 
initially determine the presence of active receptor, competitive binding was carried out.  Inverse 
agonist SR 144528 displaced 3H-CP 55,940 with a Ki = 4.74 nM (EC50 = 6.47nM , Kd = 2.73)  
(Figure 4.4B).   
However large error bars were noted at lower concentration ranges of the cold ligand 
which may be probably attributed to irregular washout of the proteoliposomes. Saturation 
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binding assay was conducted with the refolded receptor. It displayed a trend of saturation for 
Total and Specific Binding (Figure 4.5). Bmax values for Total and Specific binding were 
114576 and 38486 CPM respectively. CP 55,940 exhibited a Kd of 18.47 in the DMPC refolded 
CB2. Non Specific binding was determined to be ≥ 60% of specific binding. Known CB2 ligands 
binding to the DMPC refolded receptor were conducted by displacing 3H –CP 55,940 with 
CP55,940 (unlabelled); SR 144528 and  PY 2-64 (Figure 4.6). Assay was performed in duplicate 
(n = 2). Data represented as mean ± SEM. All ligands including agonist, inverse agonist 
displayed competitive displacement. CPM values obtained after repeated experiments with 
agonist WIN 55212-2 displayed a high degree of variability however a clear binding trend was 
observed showing ligand displacement when data was plotted with single point (n=1) values 
(Appendix A Figure 4.13). All these data suggests that we have designed and generated a very 
promising method for the in-vitro refolding of the CB2 within the DMPC. 
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Figure 4.4. Competitive ligand displacement assay with DMPC 
mediated refolded CB2. 
 
(A) Cartoon showing CB2 stabilized by DMPC lipidic environment. Adapted 
from Baneres et. al. 2011. (B) Competitive displacement of the 3H-CP55,940 
was obtained by using an increased amount of cold ligands. Binding profile of 
the inverse agonist, SR 144528 by displacing the 3H CP55940, Ki = 4.74 
nM.Assay was performed in triplicate (n = 3). Data represented as mean ± SEM. 
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The process of dialysis has limiting or cut-off efficiency. As per our observations, it is thus 
important to remove the residual SDS by adding KCl to the dialysis buffer. This will lead to the 
precipitation of the SDS by the formation of KDS (Potassium Dodecyl Sulphate) which is 
insoluble.  The increased precipitation of the SDS can be visually seen within the dialysis bag. 
Following dialysis, it should be a priority to remove the remaining SDS by centrifugation. This 
process can be facilitated by removing the protein from the dialysis set up and incubating on ice. 
Following this the proteoliposomes can be separated from the precipitated SDS by very high 
speed centrifugation. It should be noted that no exact ratio of the monodisperse protein: DMPC 
solution in 0.5% SDS is available and thus, the lipids are used in much excess.  
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Figure 4.5 Saturation Binding Activity of DMPC mediated refolded CB2 
 
Saturation binding assay was performed with membrane fractions by 
increasing the concentration of agonist, 3H CP 55940 using a fixed amount of 
target protein. A 1:1000 excess of cold CP 55,940 was added in the reaction 
mixture to account for non specific binding. Total (○) and non-specific (■) 
binding was measured and the deduced specific binding saturation isotherm 
(▲) was obtained as the difference between total and nonspecific binding. 
Assay was performed in triplicate (n = 3). Data presented as mean ± SEM. 
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Figure 4.6. Competitive Ligand Binding Activity of the CB2 receptor 
stabilized within the DMPC lipids. 
Competitive displacement of the 3H-CP55,940 was obtained by using an increased 
amount of cold ligands. Binding profile of (A) CP55,940 (unlabelled); the inverse 
agonists, (B) SR 144528 and (C) PY 2-64. Assay was performed in triplicate (n = 3). 
Data represented as mean ± SEM. 
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4.3.3 Amphipol assisted refolding  
Amphipol mediated CB2 refolding was carried out as discussed and is shown by the schematic 
Figure 4.2B. Initial competitive ligand displacement assays performed on the A8-35 mediated 
refolded CB2 (3H CP 55,940 displaced by SR 144528) displayed some degree of displacement of 
the radioactive ligand (Figure 4.7B).  However, the absolute CPM values were in a very small 
range and the error margins on the data points were large.  Nevertheless the Ki value obtained for 
the binding of SR 144528 was 6.97 nM which is well within the range of the Ki values reported 
for the SR compound (with CB2 receptors expressed in transfected mammalian cell lines). 
Binding was also conducted on separate preparations of CB2 refolded in A8-35, however no 
typical ligand displacement curves were generated (Appendix A Figure 4.14). This may be due 
to the incompatibility of the CB2 with the particular amphipols system (A8-35:Asolectin 
combination). Interestingly, the CB1 receptor displayed a decent amount of refolding and 
activity with the A8-35 asolectin (Dahmane et al., 2009). 
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Figure 4.7. CB2 refolding in Amphipol   
 
 
 (A) Cartoon depicting the stabilized CB2 receptor  within a thin layer of the 
A8-35 amphipathic detergent (also supplemented with asolectin). Adapted 
from Baneres et. al. 2011. (B)  Competitive ligand binding profile of the 3H 
CP 55940 replaced by increasing concentration of the  cold SR 144528. 
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4.3.4 General Discussions  
Amphipol assisted refolding was developed with the goal of achieving a generalized approach 
for the folding of membrane protein GPCRs. However in our case we do not see much 
appreciable ligand binding in proteins that were refolded with A8-35 and asolectin. The 
Amphipol mediated refolding method works in the same lines as that of the DMPC lipid based 
method except for that amphipols have a “protein–like” structure and the reaction system have 
been supplemented with asolectin.  Asolectin serves as a stabilization matrix. It has also been 
shown that the CB1 receptor can be refolded and stabilized even in absence of asolectin. There 
are some key considerations during amphipol mediated refolding of the CB2 receptor. The 
starting material CB2 receptor in its unfolded stage must be completely denatured, to go through 
the process of refolding. This means that the amount of SDS used in the refolding system must 
be greater than equal to 0.8%. This will ensure that the CB2 is nearly completely unfolded at the 
start of the refolding process. A big difference in the refolding procedure between the DMPC and 
the Amphipol mediated refolding is the removal procedure of the denaturant. While the SDS is 
removed in a slow and steady fashion by dialysis during DMPC assisted refolding, a more drastic 
method is preferred for the A8-35 mediated refolding. This difference may be attributed to the 
difference in the rates of association between the hydrophobic receptor core and the DMPC lipid 
or the A8-35 Amphipol. The rapid removal of SDS (or at least the majority of the SDS present in 
the solution system) was attained by the rapid addition of KCl in the excess of 150mM to that of 
the SDS concentration in the refolding mixture. There can be two routes for the generation of the 
Integral Membrane Protein – Amphipol complex (IMP-APol comp).  In some cases if the IMP is 
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yielded in the native conformation within the detergents then addition of the amphipol will result 
in the formation of the ternary complex (IMP-detergent – Apol) (Tribet et al., 2009; Zoonens et 
al., 2007) which can then undergo the process of detergent removal to form intact IMP-APol 
complexes. In these cases the Amphipol is present as a thin layer covering the hydrophobic 
surface of the protein (Zoonens et al., 2005).  
Testing the pharmacological activity of a refolded receptor provides unique challenges. 
The reconstituted receptor either in the lipids or in the Amphipol are much smaller in size 
compared to membrane fragments that are generally used for testing receptor pharmacological 
activity. Firstly,  the amount of the protein that would be required for the assay set up would be 
much lesser compared to the traditional methods using the membrane fragments. Due to this and 
the variability of the amount and quality of the protein from batch-batch it is very difficult to 
determine the exact amount of protein to be added/ well of the assay system and ligand range of 
the cold compound that needs to be added to provide a larger difference of the Counts Per 
Minute (CPM) values between the highest and the lowest ligand concentrations. A competitive 
ligand displacement assay does not have a huge dependence on the absolute quantity of the 
protein and can be conducted first to probe for the presence of receptor functional activity. Once 
functional activity has been detected, saturation binding can be conducted to determine the Bmax 
and Kd values of the receptor preparation. This order of experimentation is important as receptor 
saturation might not be observed if saturation radioligand (3H-CP 55,940) concentrations are not 
reached or if functional receptors are absent. A general guideline for setting up the saturation 
binding assay from our experience is to start from very low to medium and higher amounts of 
proteoliposomes per well of the assay system. This will ensure that the receptor amounts are low 
enough to be saturated with the given highest dose of the radioligand. At this point it may also be 
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necessary to also increase the amount of the radioligand in addition to decreasing the protein 
amount. A relatively very high amount of non-specific binding was observed in the case of the 
DMPC folded CB2 which may be due to either the presence of the  non-functional receptors or 
the presence of contaminating proteins which bind non-specifically to the 3H-CP55,940.  For the 
WIN 55212-2, the binding profile obtained was not conclusive. This may be due to the fact that 
the WIN 55212-2 being a potent agonist for the CB2 receptor would activate the receptor by the 
disruption of the intramolecular stabilizing bonds which is stabilizing the receptor structure in 
the first place. This is consistent with the observation that GPCRs (within LCPs) have yielded 
many more crystal structures with stabilizing inverse agonist, antagonist than with potent 
agonists. Furthermore the binding profile of PY2-64 compound synthesized by our group seemed 
to display high affinity binding with the CB2 receptor refolded in DMPC.  
Table 4.2 compares the binding affinities of the CB2 ligands to the native versus in vitro refolded 
CB2 receptor. Binding affinities of CB2 ligands like CP, SR and WIN vary between laboratories 
and independent experiments. The Ki values for the native receptors from transfected cell-lines 
are thus derived from the standard values from Tocris Biosciences 
(http://www.tocris.com/pharmacologicalBrowser.php?ItemId=4983#.UqZKFEAo6M8). We 
suggest several reasons to account for the difference in the binding affinities of the CB2 ligands 
between the native CB2 (expressed in the transfected mammalian cell lines) and the CB2 
refolded in the DMPC lipids. In overall the standard compounds CP 55,940 (non classical CB2 
agonist) and the SR 144528 (CB2 receptor inverse agonist) exhibit binding affinities in the range 
of (0-10 nM). These two ligands exhibit a 3 fold and 5.55 fold tighter binding with the CB2 in 
DMPC lipids (when compared to their most potent binding affinities with the native CB2).  We 
would assume that the CB2 receptor is relatively much more unstable within the DMPC than in 
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its natural membrane environment, although they might have an overall similar structure to 
exhibit functional ligand binding.  The CB2 protein in the DMPC should hence bind more tightly 
to these ligands to achieve structural stabilization and remain in the most thermodynamically 
stable state. This should be particularly true in case of the SR 144528- the inverse agonist which 
in theory should stabilize the receptor in its inactive state. Along the same lines, a potent agonist 
will lead to the disruption of stabilizing interactions within the receptor and lead to transition 
from the inactive to the active state. We understand that WIN 55212-2 binding will break the 
stabilizing interactions in the receptor and lead to structural destabilization or complete structural 
loss of the CB2 stabilized in the DMPC lipids. Considering the specific receptor saturation 
binding and the competitive ligand displacement patterns of the CP 55940 and SR 144528 
ligands, we can infer that the CB2 receptor refolded within DMPC assumes a native-like 
disposition. Surprisingly, the inverse agonist PY2-64 bound the DMPC-refolded receptor with a 
significantly lower binding affinity. A plausible explanation for this phenomenon may be 
attributed to the difference in the spatial disposition of the key amino acid residues involved in 
the PY2-64 ligand binding pocket of in vitro refolded CB2 versus the native receptor. This 
explanation however is subject to further biophysical analyses.  
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Table 4.2.Comparison of Ki values of ligands binding to the CB2 receptor obtained from transfected CHO 
cell line versus CB2 receptor obtained within the DMPC lipids.  
 
Ligand Name Ligand functionality 
Ki in transected cell 
line (CHO CB2 
membrane fractions) 
Ki  in CB2 refolded 
in DMPC 
CP 55,940 Non classical agonist 0.69-2.8 nM 0.235 nM 
WIN 55,212-2 Agonist 3.13 nM No Binding 
SR 144528 Inverse agonist 0.5-8 nM 0.09 nM 
PY2-64 Inverse agonist 0.5 nM 218 nM 
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4.4 SUMMARY AND CONCLUSION 
4.4.1 Process Summary 
In the project we started out with the goal of producing purified functional CB2 receptor in vitro 
within stabilizing environments using the E. coli as the expression host.  Successfully produced 
protein can be then used for both structural and functional studies. The overall process required 
three major steps of expression, purification, structural reconstitution in vitro. We started CB2 
expression with dual fusion tags for membrane targeted CB2 expression using Mistic and TarCF 
as the N- and C-terminal tags respectively. In spite of functional CB2 expression in the 
membrane, the system could not be taken forward for the extraction and purification due to the 
low expression level of the fusion protein. To then avoid the problems arising from the low 
expression levels of the CB2 receptor, we used IB targeted expression of CB2 receptor. Two 
expression vectors Trp∆LE-CB2 and GST-CB2 were designed for this purpose. The TrpΔLE –
CB2 system had a very high overall hydrophobicity.    High concentrations of the detergents 
were required to keep the fusion protein in solution while there was no or very less Factor Xa 
cleavage under these conditions.  The GST CB2 expression construct provided IBs with higher 
solubility. Using this system we were able to purify and carry out the process of detergent 
exchange and thrombin protease cleavage all in one step.  Further the cleaved, monodispersed 
CB2 was obtained after the size exclusion chromatography steps in 0.5% SDS which provided 
the starting material for the refolding trials. To carry out structural reconstitution or refolding in 
vitro we used Amphipols (anionic polymers). Using standard amphipol mediated refolding 
procedures we observed no or very shallow ligand binding curves. Better ligand binding was 
observed using the lipids DMPC. Binding of standard ligand CP 55, 940 (non classical CB2 
 122 
receptor agonist) was observed by both saturation binding and competitive ligand displacement 
assays. Furthermore to verify receptor functional activity competitive displacement was carried 
out with CB2 ligands SR 144528 and PY2-64 (CB2 receptor inverse agonist and neutral 
antagonist respectively). All ligands displayed classical binding patterns. Binding constant Ki 
value for the PY2-64 had about 100-1000 fold less affinity from that of the WT CB2 receptor.  
Using the GST CB2 expression purification system and the DMPC mediated refolding we were 
able to express, purify and refold the CB2 receptor in-vitro to functionality. 
4.4.2 Overall Conclusion 
The scope of functional expression of GPCRs is enormous and involves many disciplines such as 
molecular biology, protein biochemistry, protein chemistry and lipid and/or detergent chemistry. 
Our findings, however limited or case specific, have contributed to all these fields, specifically 
towards their application to membrane protein biochemistry. GPCR structural biology is in its 
early stages and high resolution structural and mechanistic information is required for a huge 
number of receptors which are very important therapeutic targets. This is due to the lack of 
robust and approachable methods involved in the production of functional GPCRs. Methods are 
either very costly, resource intensive or are not robust and repeatable. The CB2 receptor, 
particularly using the inclusion body based approach, has been isolated within lipids in 
functional form. Both approaches to produce the receptor in its functional form have made 
significant innovation in terms of vector design and methodology development. 
Mistic-CB2-TarCF construct can successfully express the CB2 receptor protein in E. coli 
C43(DE3). The obtained fusion proteins can localize at the bacterial membrane. Importantly, the 
Mistic-CB2-TarCF fusion proteins show effective binding activity with the known CB2 ligands. 
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This suggests that the conformational state of the native CB2 receptor, used for specific ligand 
binding, is retained in the presence of fusion partners. Also, we found that the fusion partners – 
Mistic and TarCF – in combination, are more effective for enhancing protein expression in E. 
coli, than their use alone. Overall findings from this present study suggest that the targeting of 
fusion partners to the bacterial membrane is critical to the conformational stability of the 
expressed CB2 protein. The possible role of the fusion partners for the overexpression and 
stabilization the CB2 protein is illustrated by the two plausible models (Fig. 2.7) for easy 
comprehension. In this putative model, the CB2 receptor structure was adapted from the 3D CB2 
model reported previously by Xie et. al (Xie et al., 2003), while the structure of Mistic and Tsr 
(structurally related to Tar) were determined by NMR (PDB:1YGM) (Roosild et al., 2005)  and 
cryo-electron microscopy (Khursigara et al., 2008) studies, respectively.   However, confirming 
the putative model will be subject to further biophysical studies. Currently, we are using the 
entire fusion protein and microscopy. The trials for 2D crystal generation will be favorably 
facilitated by the increased molecular weight of the fusion protein complex (Smyth et al., 2003). 
In our second approach we used the diametrically opposite approach for the production of 
functionally inactive CB2 inclusion bodies. A huge impetus for in vitro refolding of GPCRs was 
provided by the development of newer and developed refolding methods and matrices for 
stabilizing the receptor (Baneres et al., 2011). These methods were implemented in parallel for 
the greater chances of functional folding.  
The overall very high hydrophobicity of the Trp∆LE leader makes it difficult during the 
isolation and purification of the fusion protein. However the fusion protein had a high level of 
expression and the protein was isolated by one step pH gradient chromatography.  The biggest 
challenge we encountered with the hydrophobic protein is to carry out protease cleavage. The 
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protease greatly loses its activity in the presence of the detergents; however the detergents are 
required to keep the protein in solution. We have always observed a high degree of incomplete 
cleavage or precipitation of the Trp∆LE-CB2 in a low detergent environment. This meant that in-
spite a careful optimization of detergent environment large excess of the Factor Xa protease 
would be required which would make it very costly approach. 
The use of a construct with greater solubility e.g. the GST-CB2 has proved to be a much 
more useful approach. The GST CB2 can be stabilized in aqueous buffers with very low (upto 
even 0.05%-in our hands) of very mild detergent like DDM.  Furthermore we have also seen 
significant ability of the GST Sepharose beads to capture and remove GST/GST tagged protein 
from the solution phase in the low detergent environment. This suggests that the GST tag can 
indeed be used for both enhancing solubility and purification in IB targeted GPCR expression 
and purification.  
We have in our refolding studies generated receptor refolded within the DMPC lipids. No 
or very low receptor activity was seen for the CB2 refolding in Amphipol A8-35. Refolding to its 
functional state depends on the interplay of several physicochemical property of the receptor, the 
refolding medium and also in the process of SDS precipitation from the refolding mixture. 
In conclusion a very attractive method has been established for the production of the 
functional CB2 receptor  which can be taken over for huge number of  applications. Figure 4.8 
summarizes the overall results from each approach towards achieving our goal of producing 
functionally active CB2 receptor  in-vitro. 
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Figure 4.8. Overall summary of results from the three distinct approaches towards 
producing functionally active refolded CB2 receptor in vitro 
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4.5 FUTURE DIRECTIONS 
The future scope of the work carried out can be grouped into two areas. Firstly we will discuss 
the future scope of this study within the area of methodology development and production of 
functional CB2 from E. coli. This can be correlated to a much broader goal of design and 
implementation of faster and more robust method for the functional expression of GPCRs 
from bacterial expression systems. Secondly we will discuss the future studies that may be 
conducted on the functional CB2 arrived at this method which are likely to be carried out in 
our / collaborators laboratory. 
The development of a robust and dependable method for the functional expression of 
the CB2 receptor from the E. coli will greatly facilitate the structure function studies of the 
receptor. Firstly an optimized methodology, like we have described, greatly reduce the cost of 
GPCR protein production. Further E. coli offers the ability to produce isotopically labeled 
protein and exchange among stabilization environments e.g. Lipids to LCP/ nanodiscs for 
crystallization or receptor dynamics experiments respectively. For similar studies in the future 
we suggest the adaptation of cyclic denaturation and renaturation steps for GPCR refolding.  
Other members of the Rhodopsin family GPCRs can be subject to similar solubilization and 
on column detergent exchange and cleavage steps. As a starting point we suggest the use of 
DMPC lipids for the refolding strategy however several adjustment need to be made for 
different GPCRs. As a future study we strongly recommend the use of lipid e.g Asolectin and 
Cholesterol additives to the refolding mixture. These would perhaps help to attain better 
stabilized receptor and also determine the role of such additives in receptor stabilization. It 
would also be interesting to determine the effects of stabilizing ligands (inverse agonist e.g. 
SR 144528 for CB2) in the refolding mixture. Determination of  the stability of the refolded 
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receptor with time in normal or elevated temperatures to determine receptor thermostability. 
When working with a different GPCR all steps of expression, purification and refolding 
experiments reported here should be modified.  However, this methodology would serve as a 
starting point for future studies with other GPCRs. 
Functional CB2 receptor obtained within the DMPC may be used for a wide array of 
experiments. We would like to conduct Cryo EM studies to determine the plausible receptor 
structure and its disposition within the DMPC lipids. As stated previously the developed 
methodology can be adapted by simple modification of expression conditions to M9 media to 
produce uniformly isotopically labeled receptor. Refolded isotopically labeled CB2 may then 
be used for solid state NMR spectroscopy. With the developments of NMR spectroscopy and 
data interpretation CB2 dynamics including ligand induced receptor conformational changes 
can be monitored by solution state NMR spectroscopy. The refolded CB2 also provides a 
great platform for the Hydrogen-Deuterium exchange studies for the determination of solvent 
accessible surface area and studies on conformational activation of the receptor. 
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SUPPLEMENTARY FIGURES 
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Figure 4.9. Comparative difference of saturation binding assay of membrane 
fractions. 
Membrane fractions were prepared from  E. coli  C43(DE3) cells transformed  
with  pET21a-Mistic-CB2-TarCF  and  pET 21a-TarCF  (negative control).  
Specific Binding was obtained as a difference between the Total and Non-
Specific binding. Graph above shows the  difference of Specific Binding  
between the fusion construct and the negative control. 
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Figure 4.10. pH gradient IMAC purification chromatogram of the Trp∆LE-Xa-CB2 
fusion construct. 
(A) Trp∆LE-Xa-CB2 (53kDa) was solubilized from enriched inclusion bodies using  
1% SDS and  was loaded  into a pre-equilibrated IMAC column at pH-8.0. Non 
specific and Specific proteins were eluted at pH -7.0 and 6.0 respectively.  
Subsequent SDS-PAGE of eluted fractions and its CBB staining is shown in (B) and 
were also verified by (C) Western Blotting with Anti-His and Anti -CB2 antibodies. 
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Figure 4.11. Optimization of Trp∆LE-Xa-CB2 cleavage by Factor Xa. 
 
 
Process optimization was implemented to improve the efficiency of  Factor Xa 
cleavage. The exchanged Trp∆LE-Xa-CB2 protein was incubated with different 
concentrations (0,0.02,0.5 and 1µg) of  Factor Xa per 50 µg  of  Trp∆LE fused CB2 
receptor for 3,6,9,16 (overnight) hours (as indicated over lanes corresponding lanes). 
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Figure 4.12. Clarification of the cleaved GST-CB2 protein. 
 
 
(A)  To clarify the eluent from the uncleaved parent and the cleaved released GST the 
mixture was incubated with GST Sepharose resin pre-equilibrated with the cleavage 
buffer. Resin was separated from the liquid phase and the supernatant was separated 
on a 10% SDS PAGE and CBB stained. (B) Supernatant was probed with Anti-His, 
Anti-CB2 and Anti-GST antibodies.  
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Figure 4.13. Competitive binding of CB2 in DMPC to WIN 55212-2 mesylate 
 
Competitive displacement of the 3H-CP55,940 was obtained by using an increased 
amount of cold ligands. Binding profile of the agonist, WIN 55212-2  mesylate  salt 
form by displacing the 3H CP55,940. 
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Figure 4.14. Competitive displacement of the 3H-CP 55, 940 with the CB2 refolded 
in Amphipol A8-35 
 
CB2 receptor refolded in Amphipols was tested for ligand displacement capability with 
(A) cold CP 55,940 and (B) inverse agonist SR 144528.  
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APPENDIX B 
SUPPLEMENTARY INFORMATION 
B.1 FOOTNOTES ON CHAPTER 2 
B.1.1 Expression  of the CB2 receptor with fusion partners  
We used the bacterial thioredoxin TrxA tag as a C terminal fusion partner for the expression of 
CB2 receptor tagged to Mistic in the N-terminal to generate the final construct Mistic-CB2-
TrxA. The thioredoxin tag has been applied in several protein production applications as it 
increases the solubility of the overall fusion construct. A comparable amount of Mistic-CB2-
TarCFand the Mistic-CB2-TrxA was observed by Western Blotting (Figure 4.15). However the 
construct with the Mistic and the TarCF was used for further expression purification studies due 
to the novelty of the fusion partners. This demonstrates that the Mistic is a versatile N terminal 
fusion partner and the Mistic and TrxA in combination may also be used for GPCR membrane 
targeted expression and prurification. 
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Figure 4.15. Comparison of fusion protein expression levels. 
Western Blot analysis of whole cell lysates from bacteria 
transformed with the constructs Mistic-CB2-TrxA (63 kDa) and 
Mistic-CB2-TarCF (86 kDa).  
 
B.1.2 Comparison of the overall RMSD of the CB2 receptor between receptor homology 
models with or without the fusion partners 
To compare the differences between CB2 structure and disposition with or without the fusion 
partners we compared the root mean square deviation (RMSD) between the CB2 with or without 
fusion partners. The CB2 homology model (14517981) (which will be used for comparison with 
CB2 was fused with the Mistic and the TarCF via linker) was connected to the Mistic and the 
TarCF using linker segments. The NMR structure of Mistic (PDB:1YGM) was obtained from 
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PDB protein data bank and the homology model of the TarCF was obtained from the crystal of 
the serine chemoreceptor Tsr (PDB:2D4U). The structure of the fusion protein was arrived at by 
using the orchestar function from the Sybyl 8.0. The structures of the Mistic, CB2 and TarCF 
were incorporated without any further modification. The linker regions were generated by 
homology modeling and using proteins fragments which have very high sequence similarity and 
for which the structure are known. All components were connected by peptide bond (peptide 
bond linkage in-silico) and the overall fusion protein was subjected to energy minimization. The 
fusion protein model was saved and imported back to Sybyl window with CB2 alone. Overall 
RMSD value was 2.021 and structural deviations were seen maximally in the intracellular loop 
IL3 region (Figure 4.16). This result suggested before our functional activity assays, that Mistic 
and TarCF when linked with the linker peptides to the CB2 should not lead to significant 
structural loss of the receptor.   
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Figure 4.16. Comparison of the backbone RMSD of the CB2 receptor virtual model 
and fusion protein.  
Tripos Sybyl software 8.0 was used for fusion protein model building and RMSD 
measurement of CB2 receptor virtual model (Xie et. al. 2003)  (purple and blue) with the 
CB2 fusion protein Mistic-CB2-TarCF (yellow and red). Overall RMSD between the 
models is 2.021 and structural deviations were seen maximally in the intracellular loop 
IL3 region.  
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B.2 FOOTNOTES ON CHAPTER 3 
TROUBLESHOOTING STEPS 
B.2.1 Purification of the GST CB2 fusion protein inclusion bodies- process complications 
and troubleshooting steps 
Presence of excess amount of DNA 
Processing of the cell pellets to arrive at the enriched inclusion bodies and preparation of the load 
material from the enriched inclusion bodies both have the problem of the presence of excess 
amounts released DNA. The excess DNA will lead to the inefficient separation of the IBs from 
the solubilized protein during the IB enrichment steps. This is due to the formation of sloppy like 
material which prevent the separation of the soluble and insoluble materials. .Further the 
presence of DNA even in moderate amounts leads to high resistance during the filteration step 
prior to loading the sample to the affinity chromatography column. Loading unfiltered material 
might block the column or tubings in the AKTA system and hence it is extremely important to 
have the load material filtered before loading to the affinity column.  
To remove the excess amounts of DNA during the IB enrichment steps the sample must be well 
sonicated on ice. This will allow breakdown of majority of the contaminant DNA by shearing 
force. Care must be taken though that the sample is always maintained on ice and heating does 
not result as a result of sonication. Following sonication small amounts of universal nuclease 
might be added to the slurry to lead to further chemical breakdown. On the other hand, removing 
DNA from unclear load material should be done mostly by chemical lysis as the enriched GST 
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CB2 in the load material is much more susceptible for breakdown during harsh sonication. A 
couple of short burst (2-5 secs) of sonications should be done on ice however the majority of the 
DNA removal should be carried out by chemical lysis.  
Removal of Hydrophobic contaminants 
The process of IB enrichment can be monitored by noticing the color of the pellet. The enriched 
IB pellet should be whitish in color. If the pellet material is brownish/blackish in color it is 
suggestive of the presence of hydrophobic contaminants. Hydrophobic proteins can be removed 
by washing the pellet repeatedly with base buffer (20 mM Tris HCl, 250 mM NaCl, pH-7.5) 
supplemented with 0.5% Triton X-100. However care should be taken to achieve a balance 
between removal of unwanted material and loss of the precious enriched IB. Resuspending the 
enriched IB in the base buffer should result in a “milk-like” appearance. 
Purification of the solubilized IBs 
The solubilized IBs are stabilized within 1% Lauryl Sarkosyl and are maintained within reduced 
conditions with 10 mM β-Mercaptoethanol. The presence of the beta –ME leads to the color 
change of the IMAC column. We have observed no differences in the binding efficiency of the 
protein of interest (judged by the final protein yield). However, it would be important to wash the 
column with >20CV of the thrombin cleavage buffer prior to injecting the thrombin protease. 
This not only ensures the complete exchange of Sarkosyl with DDM but also leads to the 
complete removal of the reducing agent. 
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On column cleavage 
To ensure better thrombin cleavage the following should be very useful. The thrombin protease 
should be resuspended from powder using the thrombin cleavage freshly before injection to the 
column. The buffer containing the protease (1CV) should be injected into the column with a 
relatively higher flow rate to ensure that the protease spreads up within the column. 
 141 
BIBLIOGRAPHY 
 
Achmuller, C., Kaar, W., Ahrer, K., Wechner, P., Hahn, R., Werther, F., Schmidinger, H., 
Cserjan-Puschmann, M., Clementschitsch, F., Striedner, G., Bayer, K., Jungbauer, A., 
Auer, B., 2007. N(pro) fusion technology to produce proteins with authentic N termini in 
E. coli. Nat Methods 4, 1037-1043. 
Alexander, A., Smith, P.F., Rosengren, R.J., 2009. Cannabinoids in the treatment of cancer. 
Cancer Lett 285, 6-12. 
Aloia, A.L., Glatz, R.V., McMurchie, E.J., Leifert, W.R., 2009. GPCR expression using 
baculovirus-infected Sf9 cells. Methods Mol Biol 552, 115-129. 
Anand, P., Whiteside, G., Fowler, C.J., Hohmann, A.G., 2009. Targeting CB2 receptors and the 
endocannabinoid system for the treatment of pain. Brain Res Rev 60, 255-266. 
Anfinsen, C.B., 1973. Principles that govern the folding of protein chains. Science 181, 223-230. 
Antommattei, F.M., Munzner, J.B., Weis, R.M., 2004. Ligand-specific activation of Escherichia 
coli chemoreceptor transmethylation. J Bacteriol 186, 7556-7563. 
Arcemisbehere, L., Sen, T., Boudier, L., Balestre, M.N., Gaibelet, G., Detouillon, E., Orcel, H., 
Mendre, C., Rahmeh, R., Granier, S., Vives, C., Fieschi, F., Damian, M., Durroux, T., 
Baneres, J.L., Mouillac, B., 2010. Leukotriene BLT2 receptor monomers activate the 
G(i2) GTP-binding protein more efficiently than dimers. J Biol Chem 285, 6337-6347. 
Arnau, J., Lauritzen, C., Petersen, G.E., Pedersen, J., 2011. Reprint of: Current strategies for the 
use of affinity tags and tag removal for the purification of recombinant proteins. Protein 
Expr Purif. 
Attwood, T.K., Findlay, J.B., 1994. Fingerprinting G-protein-coupled receptors. Protein Eng 7, 
195-203. 
Bane, S.E., Velasquez, J.E., Robinson, A.S., 2007. Expression and purification of milligram 
levels of inactive G-protein coupled receptors in E. coli. Protein Expr Purif 52, 348-355. 
 142 
Baneres, J.L., Martin, A., Hullot, P., Girard, J.P., Rossi, J.C., Parello, J., 2003. Structure-based 
analysis of GPCR function: conformational adaptation of both agonist and receptor upon 
leukotriene B4 binding to recombinant BLT1. J Mol Biol 329, 801-814. 
Baneres, J.L., Mesnier, D., Martin, A., Joubert, L., Dumuis, A., Bockaert, J., 2005. Molecular 
characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy. J Biol 
Chem 280, 20253-20260. 
Baneres, J.L., Parello, J., 2003. Structure-based analysis of GPCR function: evidence for a novel 
pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-
protein. J Mol Biol 329, 815-829. 
Baneres, J.L., Popot, J.L., Mouillac, B., 2011. New advances in production and functional 
folding of G-protein-coupled receptors. Trends Biotechnol 29, 314-322. 
Baneyx, F., 1999. Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 10, 
411-421. 
Basu, S., Dittel, B.N., 2011. Unraveling the complexities of cannabinoid receptor 2 (CB2) 
immune regulation in health and disease. Immunol Res 51, 26-38. 
Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R., Vogel, Z., 1995. The 
peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. 
FEBS Lett 375, 143-147. 
Berger, C., Ho, J.T., Kimura, T., Hess, S., Gawrisch, K., Yeliseev, A., 2010. Preparation of 
stable isotope-labeled peripheral cannabinoid receptor CB2 by bacterial fermentation. 
Protein Expr Purif 70, 236-247. 
Bessette, P.H., Aslund, F., Beckwith, J., Georgiou, G., 1999. Efficient folding of proteins with 
multiple disulfide bonds in the Escherichia coli cytoplasm. Proc Natl Acad Sci U S A 96, 
13703-13708. 
Bjarnadottir, T.K., Gloriam, D.E., Hellstrand, S.H., Kristiansson, H., Fredriksson, R., Schioth, 
H.B., 2006. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled 
receptors in human and mouse. Genomics 88, 263-273. 
Blain, K.Y., Kwiatkowski, W., Choe, S., 2010. The functionally active Mistic-fused histidine 
kinase receptor, EnvZ. Biochemistry 49, 9089-9095. 
Booth, P.J., Curran, A.R., 1999. Membrane protein folding. Curr Opin Struct Biol 9, 115-121. 
Bouaboula, M., Desnoyer, N., Carayon, P., Combes, T., Casellas, P., 1999a. Gi protein 
modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor 
CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55, 473-
480. 
 143 
Bouaboula, M., Dussossoy, D., Casellas, P., 1999b. Regulation of peripheral cannabinoid 
receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for 
receptor biological responses. J Biol Chem 274, 20397-20405. 
Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrie, B., Rinaldi-Carmona, M., 
Calandra, B., Le Fur, G., Casellas, P., 1996. Signaling pathway associated with 
stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-
activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237, 704-
711. 
Bradley, L.H., Wei, Y., Thumfort, P., Wurth, C., Hecht, M.H., 2007. Protein design by binary 
patterning of polar and nonpolar amino acids. Methods Mol Biol 352, 155-166. 
Cabral, G.A., Griffin-Thomas, L., 2009. Emerging role of the cannabinoid receptor CB2 in 
immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 
11, e3. 
Cabral, G.A., Raborn, E.S., Griffin, L., Dennis, J., Marciano-Cabral, F., 2008. CB2 receptors in 
the brain: role in central immune function. Br J Pharmacol 153, 240-251. 
Cahill, K., Ussher, M., 2007. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking 
cessation. Cochrane Database Syst Rev, CD005353. 
Capasso, R., Borrelli, F., Aviello, G., Romano, B., Scalisi, C., Capasso, F., Izzo, A.A., 2008. 
Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory 
hypermotility in mice. Br J Pharmacol 154, 1001-1008. 
Cheng, Y., Hitchcock, S.A., 2007. Targeting cannabinoid agonists for inflammatory and 
neuropathic pain. Expert Opin Investig Drugs 16, 951-965. 
Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., 
Choi, H.J., Kuhn, P., Weis, W.I., Kobilka, B.K., Stevens, R.C., 2007. High-resolution 
crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. 
Science 318, 1258-1265. 
Chow, M.K., Amin, A.A., Fulton, K.F., Fernando, T., Kamau, L., Batty, C., Louca, M., Ho, S., 
Whisstock, J.C., Bottomley, S.P., Buckle, A.M., 2006. The REFOLD database: a tool for 
the optimization of protein expression and refolding. Nucleic Acids Res 34, D207-212. 
Chowdhury, A., Feng, R., Tong, Q., Zhang, Y., Xie, X.Q., 2012. Mistic and TarCF as fusion 
protein partners for functional expression of the cannabinoid receptor 2 in Escherichia 
coli. Protein Expr Purif 83, 128-134. 
Cook, G.A., Stefer, S., Opella, S.J., 2011. Expression and purification of the membrane protein 
p7 from hepatitis C virus. Biopolymers 96, 32-40. 
Cordes, M.H., Davidson, A.R., Sauer, R.T., 1996. Sequence space, folding and protein design. 
Curr Opin Struct Biol 6, 3-10. 
 144 
Dahmane, T., Damian, M., Mary, S., Popot, J.L., Baneres, J.L., 2009. Amphipol-assisted in vitro 
folding of G protein-coupled receptors. Biochemistry 48, 6516-6521. 
Derynck, R., Roberts, A.B., Winkler, M.E., Chen, E.Y., Goeddel, D.V., 1984. Human 
transforming growth factor-alpha: precursor structure and expression in E. coli. Cell 38, 
287-297. 
Dorsam, R.T., Gutkind, J.S., 2007. G-protein-coupled receptors and cancer. Nat Rev Cancer 7, 
79-94. 
Elphick, M.R., Egertova, M., 2001. The neurobiology and evolution of cannabinoid signalling. 
Philos Trans R Soc Lond B Biol Sci 356, 381-408. 
Fernandez-Escamilla, A.M., Rousseau, F., Schymkowitz, J., Serrano, L., 2004. Prediction of 
sequence-dependent and mutational effects on the aggregation of peptides and proteins. 
Nat Biotechnol 22, 1302-1306. 
Foord, S.M., Bonner, T.I., Neubig, R.R., Rosser, E.M., Pin, J.P., Davenport, A.P., Spedding, M., 
Harmar, A.J., 2005. International Union of Pharmacology. XLVI. G protein-coupled 
receptor list. Pharmacol Rev 57, 279-288. 
Fortin, D.A., Levine, E.S., 2007. Differential effects of endocannabinoids on glutamatergic and 
GABAergic inputs to layer 5 pyramidal neurons. Cereb Cortex 17, 163-174. 
Freigassner, M., Pichler, H., Glieder, A., 2009. Tuning microbial hosts for membrane protein 
production. Microb Cell Fact 8, 69. 
Gaidamovich, S., Obukhova, V.R., Sveshnikova, N.A., Cherednichenko Iu, N., Kostiukov, M.A., 
1978. [Natural foci of viruses borne by Phlebotomus papatasi in the USSR according to a 
serologic study of the population]. Vopr Virusol, 556-560. 
Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., 
Shire, D., Le Fur, G., Casellas, P., 1995a. Expression of central and peripheral 
cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J 
Biochem 232, 54-61. 
Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., 
Shire, D., Le Fur, G., Casellas, P., 1995b. Expression of central and peripheral 
cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J 
Biochem 232, 54-61. 
Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D., Hipkin, R.W., 2000. Endocannabinoid 
2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: 
antagonism by anandamide. Mol Pharmacol 57, 1045-1050. 
Grisshammer, R., 2009. Purification of recombinant G-protein-coupled receptors. Methods 
Enzymol 463, 631-645. 
 145 
Grisshammer, R., Duckworth, R., Henderson, R., 1993. Expression of a rat neurotensin receptor 
in Escherichia coli. Biochem J 295 ( Pt 2), 571-576. 
Grisshammer, R., Little, J., Aharony, D., 1994. Expression of rat NK-2 (neurokinin A) receptor 
in E. coli. Receptors Channels 2, 295-302. 
Grisshammer, R., Tate, C.G., 1995. Overexpression of integral membrane proteins for structural 
studies. Q Rev Biophys 28, 315-422. 
Hampson, R.E., Deadwyler, S.A., 1999. Cannabinoids, hippocampal function and memory. Life 
Sci 65, 715-723. 
Hecht, M.H., Das, A., Go, A., Bradley, L.H., Wei, Y., 2004. De novo proteins from designed 
combinatorial libraries. Protein Sci 13, 1711-1723. 
Hockney, R.C., 1994. Recent developments in heterologous protein production in Escherichia 
coli. Trends Biotechnol 12, 456-463. 
Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., 
Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, R.G., 2002. 
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. 
Pharmacol Rev 54, 161-202. 
Hwang, P.M., Pan, J.S., Sykes, B.D., 2012. A PagP fusion protein system for the expression of 
intrinsically disordered proteins in Escherichia coli. Protein Expr Purif 85, 148-151. 
Hwang, P.M., Pan, J.S., Sykes, B.D., 2013. Targeted expression, purification, and cleavage of 
fusion proteins from inclusion bodies in Escherichia coli. FEBS Lett. 
Jaakola, V.P., Griffith, M.T., Hanson, M.A., Cherezov, V., Chien, E.Y., Lane, J.R., Ijzerman, 
A.P., Stevens, R.C., 2008. The 2.6 angstrom crystal structure of a human A2A adenosine 
receptor bound to an antagonist. Science 322, 1211-1217. 
Kamerlin, S.C., Sharma, P.K., Chu, Z.T., Warshel, A., 2010. Ketosteroid isomerase provides 
further support for the idea that enzymes work by electrostatic preorganization. Proc Natl 
Acad Sci U S A 107, 4075-4080. 
Kaminski, N.E., 1996. Immune regulation by cannabinoid compounds through the inhibition of 
the cyclic AMP signaling cascade and altered gene expression. Biochem Pharmacol 52, 
1133-1140. 
Kaminski, N.E., 1998. Inhibition of the cAMP signaling cascade via cannabinoid receptors: a 
putative mechanism of immune modulation by cannabinoid compounds. Toxicol Lett 
102-103, 59-63. 
Kang, N., Koo, J., 2012. Olfactory receptors in non-chemosensory tissues. BMB Rep 45, 612-
622. 
 146 
Kapust, R.B., Waugh, D.S., 1999. Escherichia coli maltose-binding protein is uncommonly 
effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 8, 
1668-1674. 
Kawamura, M., Azuma, N., Kohsaka, S., 1989. [Experimental studies on microphthalmos 
formation in neonatal rats treated with monosodium-L-glutamate]. Nihon Ganka Gakkai 
Zasshi 93, 553-561. 
Kefala, G., Kwiatkowski, W., Esquivies, L., Maslennikov, I., Choe, S., 2007. Application of 
Mistic to improving the expression and membrane integration of histidine kinase 
receptors from Escherichia coli. J Struct Funct Genomics 8, 167-172. 
Kelly, D.L., Gorelick, D.A., Conley, R.R., Boggs, D.L., Linthicum, J., Liu, F., Feldman, S., Ball, 
M.P., Wehring, H.J., McMahon, R.P., Huestis, M.A., Heishman, S.J., Warren, K.R., 
Buchanan, R.W., 2011. Effects of the cannabinoid-1 receptor antagonist rimonabant on 
psychiatric symptoms in overweight people with schizophrenia: a randomized, double-
blind, pilot study. J Clin Psychopharmacol 31, 86-91. 
Khursigara, C.M., Wu, X., Zhang, P., Lefman, J., Subramaniam, S., 2008. Role of HAMP 
domains in chemotaxis signaling by bacterial chemoreceptors. Proc Natl Acad Sci U S A 
105, 16555-16560. 
Kiefer, H., Krieger, J., Olszewski, J.D., Von Heijne, G., Prestwich, G.D., Breer, H., 1996. 
Expression of an olfactory receptor in Escherichia coli: purification, reconstitution, and 
ligand binding. Biochemistry 35, 16077-16084. 
Kim, T.K., Zhang, R., Feng, W., Cai, J., Pierce, W., Song, Z.H., 2005. Expression and 
characterization of human CB1 cannabinoid receptor in methylotrophic yeast Pichia 
pastoris. Protein Expr Purif 40, 60-70. 
Kobilka, B.K., Deupi, X., 2007. Conformational complexity of G-protein-coupled receptors. 
Trends Pharmacol Sci 28, 397-406. 
Kolakowski, L.F., Jr., 1994. GCRDb: a G-protein-coupled receptor database. Receptors 
Channels 2, 1-7. 
Korepanova, A., Gao, F.P., Hua, Y., Qin, H., Nakamoto, R.K., Cross, T.A., 2005. Cloning and 
expression of multiple integral membrane proteins from Mycobacterium tuberculosis in 
Escherichia coli. Protein Sci 14, 148-158. 
Krepkiy, D., Gawrisch, K., Yeliseev, A., 2007. Expression and purification of CB2 for NMR 
studies in micellar solution. Protein Pept Lett 14, 1031-1037. 
Krepkiy, D., Wong, K., Gawrisch, K., Yeliseev, A., 2006. Bacterial expression of functional, 
biotinylated peripheral cannabinoid receptor CB2. Protein Expr Purif 49, 60-70. 
Krikos, A., Conley, M.P., Boyd, A., Berg, H.C., Simon, M.I., 1985. Chimeric chemosensory 
transducers of Escherichia coli. Proc Natl Acad Sci U S A 82, 1326-1330. 
 147 
Kristiansen, K., 2004. Molecular mechanisms of ligand binding, signaling, and regulation within 
the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis 
approaches to receptor structure and function. Pharmacol Ther 103, 21-80. 
Kubitschek, H.E., 1990. Cell volume increase in Escherichia coli after shifts to richer media. J 
Bacteriol 172, 94-101. 
Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., Hendrickson, W.A., 1998. 
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and 
a neutralizing human antibody. Nature 393, 648-659. 
Landick, R., Carey, J., Yanofsky, C., 1985. Translation activates the paused transcription 
complex and restores transcription of the trp operon leader region. Proc Natl Acad Sci U 
S A 82, 4663-4667. 
LaVallie, E.R., DiBlasio, E.A., Kovacic, S., Grant, K.L., Schendel, P.F., McCoy, J.M., 1993. A 
thioredoxin gene fusion expression system that circumvents inclusion body formation in 
the E. coli cytoplasm. Biotechnology (N Y) 11, 187-193. 
Lee, J.H., Kim, J.H., Hwang, S.W., Lee, W.J., Yoon, H.K., Lee, H.S., Hong, S.S., 2000. High-
level expression of antimicrobial peptide mediated by a fusion partner reinforcing 
formation of inclusion bodies. Biochem Biophys Res Commun 277, 575-580. 
Lee, S.Y., 1996. High cell-density culture of Escherichia coli. Trends Biotechnol 14, 98-105. 
Leifert, W.R., Bucco, O., Abeywardena, M.Y., Patten, G.S., 2009. Radioligand binding assays: 
application of [(125)I]angiotensin II receptor binding. Methods Mol Biol 552, 131-141. 
Lozano-Ondoua, A.N., Wright, C., Vardanyan, A., King, T., Largent-Milnes, T.M., Nelson, M., 
Jimenez-Andrade, J.M., Mantyh, P.W., Vanderah, T.W., 2010. A cannabinoid 2 receptor 
agonist attenuates bone cancer-induced pain and bone loss. Life Sci 86, 646-653. 
Luca, S., White, J.F., Sohal, A.K., Filippov, D.V., van Boom, J.H., Grisshammer, R., Baldus, M., 
2003. The conformation of neurotensin bound to its G protein-coupled receptor. Proc 
Natl Acad Sci U S A 100, 10706-10711. 
Lundstrom, K., 2005. Structural genomics of GPCRs. Trends Biotechnol 23, 103-108. 
Margreiter, G., Schwanninger, M., Bayer, K., Obinger, C., 2008. Impact of different cultivation 
and induction regimes on the structure of cytosolic inclusion bodies of TEM1-beta-
lactamase. Biotechnol J 3, 1245-1255. 
Marston, F.A., 1986. The purification of eukaryotic polypeptides synthesized in Escherichia coli. 
Biochem J 240, 1-12. 
Martin-Moreno, A.M., Reigada, D., Ramirez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, 
A., de Ceballos, M.L., 2011. Cannabidiol and other cannabinoids reduce microglial 
activation in vitro and in vivo: relevance to Alzheimers' disease. Mol Pharmacol. 
 148 
Mazina, K.E., Strader, C.D., Fong, T.M., 1994. Expression and solubilization of a recombinant 
human neurokinin-1 receptor in insect cells. J Recept Res 14, 63-73. 
McAllister, G., Charlesworth, A., Snodin, C., Beer, M.S., Noble, A.J., Middlemiss, D.N., 
Iversen, L.L., Whiting, P., 1992. Molecular cloning of a serotonin receptor from human 
brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A 89, 5517-5521. 
Meir, Y., Jakovljevic, V., Oleksiuk, O., Sourjik, V., Wingreen, N.S., 2010. Precision and kinetics 
of adaptation in bacterial chemotaxis. Biophys J 99, 2766-2774. 
Michalke, K., Huyghe, C., Lichiere, J., Graviere, M.E., Siponen, M., Sciara, G., Lepaul, I., 
Wagner, R., Magg, C., Rudolph, R., Cambillau, C., Desmyter, A., 2010. Mammalian G 
protein-coupled receptor expression in Escherichia coli: II. Refolding and biophysical 
characterization of mouse cannabinoid receptor 1 and human parathyroid hormone 
receptor 1. Anal Biochem 401, 74-80. 
Miller, D., Charalambous, K., Rotem, D., Schuldiner, S., Curnow, P., Booth, P.J., 2009. In vitro 
unfolding and refolding of the small multidrug transporter EmrE. J Mol Biol 393, 815-
832. 
Miroux, B., Walker, J.E., 1996. Over-production of proteins in Escherichia coli: mutant hosts 
that allow synthesis of some membrane proteins and globular proteins at high levels. J 
Mol Biol 260, 289-298. 
Misawa, S., Kumagai, I., 1999. Refolding of therapeutic proteins produced in Escherichia coli as 
inclusion bodies. Biopolymers 51, 297-307. 
Montero, C., Campillo, N.E., Goya, P., Paez, J.A., 2005. Homology models of the cannabinoid 
CB1 and CB2 receptors. A docking analysis study. Eur J Med Chem 40, 75-83. 
Moses, V., Prevost, C., 1966. Catabolite repression of beta-galactosidase synthesis in Escherichia 
coli. Biochem J 100, 336-353. 
Muller, I., Sarramegna, V., Renault, M., Lafaquiere, V., Sebai, S., Milon, A., Talmont, F., 2008. 
The full-length mu-opioid receptor: a conformational study by circular dichroism in 
trifluoroethanol and membrane-mimetic environments. J Membr Biol 223, 49-57. 
Munro, S., Thomas, K.L., Abu-Shaar, M., 1993. Molecular characterization of a peripheral 
receptor for cannabinoids. Nature 365, 61-65. 
Naider, F., Estephan, R., Englander, J., Suresh Babu, V.V., Arevalo, E., Samples, K., Becker, 
J.M., 2004. Sexual conjugation in yeast: A paradigm to study G-protein-coupled receptor 
domain structure. Biopolymers 76, 119-128. 
Nowell, K.W., Pettit, D.A., Cabral, W.A., Zimmerman, H.W., Jr., Abood, M.E., Cabral, G.A., 
1998. High-level expression of the human CB2 cannabinoid receptor using a baculovirus 
system. Biochem Pharmacol 55, 1893-1905. 
 149 
Onaivi, E.S., 2006. Neuropsychobiological evidence for the functional presence and expression 
of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54, 231-246. 
Opekarova, M., Tanner, W., 2003. Specific lipid requirements of membrane proteins--a putative 
bottleneck in heterologous expression. Biochim Biophys Acta 1610, 11-22. 
Pacher, P., Mechoulam, R., 2011. Is lipid signaling through cannabinoid 2 receptors part of a 
protective system? Prog Lipid Res 50, 193-211. 
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., 
Teller, D.C., Okada, T., Stenkamp, R.E., Yamamoto, M., Miyano, M., 2000. Crystal 
structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-745. 
Park, S.H., Das, B.B., Casagrande, F., Tian, Y., Nothnagel, H.J., Chu, M., Kiefer, H., Maier, K., 
De Angelis, A.A., Marassi, F.M., Opella, S.J., 2012. Structure of the chemokine receptor 
CXCR1 in phospholipid bilayers. Nature 491, 779-783. 
Park, S.H., Prytulla, S., De Angelis, A.A., Brown, J.M., Kiefer, H., Opella, S.J., 2006. High-
resolution NMR spectroscopy of a GPCR in aligned bicelles. J Am Chem Soc 128, 7402-
7403. 
Patel, K.D., Davison, J.S., Pittman, Q.J., Sharkey, K.A., 2010. Cannabinoid CB(2) receptors in 
health and disease. Curr Med Chem 17, 1393-1410. 
Pertwee, R.G., 2001. Cannabinoid receptors and pain. Prog Neurobiol 63, 569-611. 
Pertwee, R.G., 2006. The pharmacology of cannabinoid receptors and their ligands: an overview. 
Int J Obes (Lond) 30 Suppl 1, S13-18. 
Pertwee, R.G., 2008. The diverse CB1 and CB2 receptor pharmacology of three plant 
cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-
tetrahydrocannabivarin. Br J Pharmacol 153, 199-215. 
Rasmussen, S.G., Choi, H.J., Fung, J.J., Pardon, E., Casarosa, P., Chae, P.S., Devree, B.T., 
Rosenbaum, D.M., Thian, F.S., Kobilka, T.S., Schnapp, A., Konetzki, I., Sunahara, R.K., 
Gellman, S.H., Pautsch, A., Steyaert, J., Weis, W.I., Kobilka, B.K., 2011. Structure of a 
nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469, 175-180. 
Rasmussen, S.G., Choi, H.J., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., Edwards, P.C., 
Burghammer, M., Ratnala, V.R., Sanishvili, R., Fischetti, R.F., Schertler, G.F., Weis, 
W.I., Kobilka, B.K., 2007. Crystal structure of the human beta2 adrenergic G-protein-
coupled receptor. Nature 450, 383-387. 
Reeves, P.J., Kim, J.M., Khorana, H.G., 2002. Structure and function in rhodopsin: a 
tetracycline-inducible system in stable mammalian cell lines for high-level expression of 
opsin mutants. Proc Natl Acad Sci U S A 99, 13413-13418. 
 150 
Roosild, T.P., Greenwald, J., Vega, M., Castronovo, S., Riek, R., Choe, S., 2005. NMR structure 
of Mistic, a membrane-integrating protein for membrane protein expression. Science 307, 
1317-1321. 
Rosenbaum, D.M., Cherezov, V., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., 
Choi, H.J., Yao, X.J., Weis, W.I., Stevens, R.C., Kobilka, B.K., 2007. GPCR engineering 
yields high-resolution structural insights into beta2-adrenergic receptor function. Science 
318, 1266-1273. 
Rosenbaum, D.M., Rasmussen, S.G., Kobilka, B.K., 2009. The structure and function of G-
protein-coupled receptors. Nature 459, 356-363. 
Rosenbaum, D.M., Zhang, C., Lyons, J.A., Holl, R., Aragao, D., Arlow, D.H., Rasmussen, S.G., 
Choi, H.J., Devree, B.T., Sunahara, R.K., Chae, P.S., Gellman, S.H., Dror, R.O., Shaw, 
D.E., Weis, W.I., Caffrey, M., Gmeiner, P., Kobilka, B.K., 2011. Structure and function 
of an irreversible agonist-beta(2) adrenoceptor complex. Nature 469, 236-240. 
Russo, E., 2003. The birth of biotechnology. Nature 421, 456-457. 
Sarramegna, V., Talmont, F., Demange, P., Milon, A., 2003a. Heterologous expression of G-
protein-coupled receptors: comparison of expression systems from the standpoint of 
large-scale production and purification. Cell Mol Life Sci 60, 1529-1546. 
Sarramegna, V., Talmont, F., Demange, P., Milon, A., 2003b. Heterologous expression of G-
protein-coupled receptors: comparison of expression systems fron the standpoint of large-
scale production and purification. Cell Mol Life Sci 60, 1529-1546. 
Simonds, W.F., 1999. G protein regulation of adenylate cyclase. Trends Pharmacol Sci 20, 66-
73. 
Smith, D.B., Johnson, K.S., 1988. Single-step purification of polypeptides expressed in 
Escherichia coli as fusions with glutathione S-transferase. Gene 67, 31-40. 
Smyth, D.R., Mrozkiewicz, M.K., McGrath, W.J., Listwan, P., Kobe, B., 2003. Crystal structures 
of fusion proteins with large-affinity tags. Protein Sci 12, 1313-1322. 
Sumiyoshi, T., Higuchi, Y., Uehara, T., 2013. Neural Basis for the Ability of Atypical 
Antipsychotic Drugs to Improve Cognition in Schizophrenia. Front Behav Neurosci 7, 
140. 
Tan, C.M., Brady, A.E., Nickols, H.H., Wang, Q., Limbird, L.E., 2004. Membrane trafficking of 
G protein-coupled receptors. Annu Rev Pharmacol Toxicol 44, 559-609. 
Tiraboschi, P., Hansen, L.A., Thal, L.J., Corey-Bloom, J., 2004. The importance of neuritic 
plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989. 
 151 
Tolon, R.M., Nunez, E., Pazos, M.R., Benito, C., Castillo, A.I., Martinez-Orgado, J.A., Romero, 
J., 2009. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-
amyloid removal by human macrophages. Brain Res 1283, 148-154. 
Tribet, C., Diab, C., Dahmane, T., Zoonens, M., Popot, J.L., Winnik, F.M., 2009. 
Thermodynamic characterization of the exchange of detergents and amphipols at the 
surfaces of integral membrane proteins. Langmuir 25, 12623-12634. 
Trzaskowski, B., Latek, D., Yuan, S., Ghoshdastider, U., Debinski, A., Filipek, S., 2012. Action 
of molecular switches in GPCRs--theoretical and experimental studies. Curr Med Chem 
19, 1090-1109. 
Venkatakrishnan, A.J., Deupi, X., Lebon, G., Tate, C.G., Schertler, G.F., Babu, M.M., 2013. 
Molecular signatures of G-protein-coupled receptors. Nature 494, 185-194. 
Vidovic, V., Prongidi-Fix, L., Bechinger, B., Werten, S., 2009. Production and isotope labeling 
of antimicrobial peptides in Escherichia coli by means of a novel fusion partner that 
enables high-yield insoluble expression and fast purification. J Pept Sci 15, 278-284. 
Villaverde, A., Carrio, M.M., 2003. Protein aggregation in recombinant bacteria: biological role 
of inclusion bodies. Biotechnol Lett 25, 1385-1395. 
von Heijne, G., 2011. Introduction to theme "membrane protein folding and insertion". Annu 
Rev Biochem 80, 157-160. 
Wacker, M., Linton, D., Hitchen, P.G., Nita-Lazar, M., Haslam, S.M., North, S.J., Panico, M., 
Morris, H.R., Dell, A., Wren, B.W., Aebi, M., 2002. N-linked glycosylation in 
Campylobacter jejuni and its functional transfer into E. coli. Science 298, 1790-1793. 
Wasik, A.M., Christensson, B., Sander, B., 2011. The role of cannabinoid receptors and the 
endocannabinoid system in mantle cell lymphoma and other non-Hodgkin lymphomas. 
Semin Cancer Biol 21, 313-321. 
Weik, M., Zaccai, G., Dencher, N.A., Oesterhelt, D., Hauss, T., 1998. Structure and hydration of 
the M-state of the bacteriorhodopsin mutant D96N studied by neutron diffraction. J Mol 
Biol 275, 625-634. 
Weiss, H.M., Grisshammer, R., 2002a. Purification and characterization of the human adenosine 
A(2a) receptor functionally expressed in Escherichia coli. Eur J Biochem 269, 82-92. 
Weiss, H.M., Grisshammer, R., 2002b. Purification and characterization of the human adenosine 
A(2a) receptor functionally expressed in Escherichia coli. European Journal of 
Biochemistry 269, 82-92. 
Weiss, H.M., Haase, W., Michel, H., Reilander, H., 1998. Comparative biochemical and 
pharmacological characterization of the mouse 5HT5A 5-hydroxytryptamine receptor and 
the human beta2-adrenergic receptor produced in the methylotrophic yeast Pichia 
pastoris. Biochem J 330 ( Pt 3), 1137-1147. 
 152 
Wickman, K., Clapham, D.E., 1995. Ion channel regulation by G proteins. Physiol Rev 75, 865-
885. 
Wolfenden, R., 2007. Experimental measures of amino acid hydrophobicity and the topology of 
transmembrane and globular proteins. J Gen Physiol 129, 357-362. 
Wright, K.L., Duncan, M., Sharkey, K.A., 2008. Cannabinoid CB2 receptors in the 
gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153, 
263-270. 
Xie, X.Q., Chen, J.Z., Billings, E.M., 2003. 3D structural model of the G-protein-coupled 
cannabinoid CB2 receptor. Proteins 53, 307-319. 
Xie, X.Q., Zhao, J., Zheng, H., 2004. Expression, purification, and isotope labeling of 
cannabinoid CB2 receptor fragment, CB2(180-233). Protein Expr Purif 38, 61-68. 
Yeliseev, A., Zoubak, L., Gawrisch, K., 2007. Use of dual affinity tags for expression and 
purification of functional peripheral cannabinoid receptor. Protein Expr Purif 53, 153-
163. 
Yeliseev, A.A., Wong, K.K., Soubias, O., Gawrisch, K., 2005. Expression of human peripheral 
cannabinoid receptor for structural studies. Protein Sci 14, 2638-2653. 
Zajicek, J.P., Apostu, V.I., 2011. Role of cannabinoids in multiple sclerosis. CNS Drugs 25, 187-
201. 
Zhang, Y., Xie, X.Q., 2008. Biosynthesis, purification, and characterization of a cannabinoid 
receptor 2 fragment (CB2(271-326)). Protein Expr Purif 59, 249-257. 
Zhang, Y., Xie, Z., Wang, L., Schreiter, B., Lazo, J.S., Gertsch, J., Xie, X.Q., 2011. Mutagenesis 
and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand 
recognition and signal transduction for CB2 receptor. Int Immunopharmacol 11, 1303-
1310. 
Zheng, H., Zhao, J., Sheng, W., Xie, X.Q., 2006. A transmembrane helix-bundle from G-protein 
coupled receptor CB2: biosynthesis, purification, and NMR characterization. 
Biopolymers 83, 46-61. 
Zheng, H., Zhao, J., Wang, S., Lin, C.M., Chen, T., Jones, D.H., Ma, C., Opella, S., Xie, X.Q., 
2005. Biosynthesis and purification of a hydrophobic peptide from transmembrane 
domains of G-protein-coupled CB2 receptor. J Pept Res 65, 450-458. 
Zhou, X.E., Melcher, K., Xu, H.E., 2012. Structure and activation of rhodopsin. Acta Pharmacol 
Sin 33, 291-299. 
Zoonens, M., Catoire, L.J., Giusti, F., Popot, J.L., 2005. NMR study of a membrane protein in 
detergent-free aqueous solution. Proc Natl Acad Sci U S A 102, 8893-8898. 
 153 
Zoonens, M., Giusti, F., Zito, F., Popot, J.L., 2007. Dynamics of membrane protein/amphipol 
association studied by Forster resonance energy transfer: implications for in vitro studies 
of amphipol-stabilized membrane proteins. Biochemistry 46, 10392-10404. 
Zuo, X., Li, S., Hall, J., Mattern, M.R., Tran, H., Shoo, J., Tan, R., Weiss, S.R., Butt, T.R., 2005. 
Enhanced expression and purification of membrane proteins by SUMO fusion in 
Escherichia coli. J Struct Funct Genomics 6, 103-111. 
 
 
